Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
1-methylethyl 2-oxo-4-(trifluoromethyl)-2H-chromen-7-yl methylphosphonate + H2O
?
-
-
-
?
1-methylethyl 4-methyl-2-oxo-2H-chromen-7-yl methylphosphonate + H2O
?
-
-
-
?
2,4-dinitrophenyl diethyl phosphate + H2O
2,4-dinitrophenol + diethyl phosphate
-
-
-
?
2,6-difluorophenyl diethyl phosphate + H2O
2,6-difluorophenol + diethyl phosphate
-
-
-
?
2-fluoro-4-nitrophenyl diethyl phosphate + H2O
2-fluoro-4-nitrophenol + diethyl phosphate
-
-
-
?
2-methylpropyl 2-oxo-4-(trifluoromethyl)-2H-chromen-7-yl methylphosphonate + H2O
?
-
-
-
?
2-oxo-4-(trifluoromethyl)-2H-chromen-7-yl N,N,N',N'-tetramethyldiamidophosphate + H2O
?
-
-
-
?
3,5-dinitrophenyl diethyl phosphate + H2O
3,5-dinitrophenol + diethyl phosphate
-
-
-
?
3-chloro-4-methyl-2-oxo-2H-chromen-7-yl 1-methylethyl methylphosphonate + H2O
?
-
-
-
?
3-chloro-4-methyl-2-oxo-2H-chromen-7-yl 2-methylpropyl methylphosphonate + H2O
?
-
-
-
?
3-chloro-4-methyl-2-oxo-2H-chromen-7-yl cyclohexyl methylphosphonate + H2O
?
-
-
-
?
3-chloro-4-methyl-2-oxo-2H-chromen-7-yl diethyl phosphate + H2O
?
-
-
-
?
3-chloro-4-methyl-2-oxo-2H-chromen-7-yl dimethyl phosphate + H2O
?
-
-
-
?
3-chloro-4-methyl-2-oxo-2H-chromen-7-yl ethyl methylphosphonate + H2O
3-chloro-7-hydroxy-4-methyl-2H-chromen-2-one + ethyl methylphosphonate
-
-
-
?
3-cyanophenyl diethyl phosphate + H2O
3-cyanophenol + diethyl phosphate
-
-
-
?
3-fluoro-4-nitrophenyl diethyl phosphate + H2O
3-fluoro-4-nitrophenol + diethyl phosphate
-
-
-
?
3-fluorophenyl diethyl phosphate + H2O
3-fluorophenol + diethyl phosphate
-
-
-
?
3-nitrophenyl diethyl phosphate + H2O
3-nitrophenol + diethyl phosphate
-
-
-
?
4-acetoxy acetophenone + H2O
?
-
-
-
?
4-chlorophenyl diethyl phosphate + H2O
4-chlorophenol + diethyl phosphate
-
-
-
?
4-cyanophenyl diethyl phosphate + H2O
4-cyanophenol + diethyl phosphate
-
-
-
?
4-diethyl phosphate acetophenone + H2O
4-hydroxyacetophenone + diethyl phosphate
-
-
-
?
4-diethyl phosphate benzaldehyde + H2O
4-hydroxybenzaldehyde + diethyl phosphate
-
-
-
?
4-diethyl phosphate methyl benzoate + H2O
methyl 4-hydroxybenzoate + diethyl phosphate
-
-
-
?
4-methyl-2-oxo-2H-chromen-7-yl 2-methylpropyl methylphosphonate + H2O
2-methylpropyl methylphosphonate + 7-hydroxy-4-methyl-2H-1-benzopyran-2-one
-
-
-
?
4-methyl-2-oxo-2H-chromen-7-yl N,N,N',N'-tetramethyldiamidophosphate + H2O
N,N,N',N'-tetramethylphosphorodiamidic acid + 7-hydroxy-4-methyl-2H-1-benzopyran-2-one
-
-
-
?
4-nitrophenyl diethyl phosphate + H2O
4-nitrophenol + diethyl phosphate
-
-
-
?
5-(thiobutyryl)butyrolactone + H2O
?
-
-
-
?
7-diethylphosphoro-3-cyanocoumarin + H2O
3-cyanocoumarin + diethyl phosphate
-
-
-
?
7-O-diethylphosphoryl-3-cyano-7-hydroxycoumarin + H2O
?
-
-
-
?
9-(2,4-dimethylphenoxycarbonyl)-10-methylacridinium triflate + H2O
?
synthesis method, overview. The assay is based on the PON1-mediated hydrolysis of an acridinium ester, and the hydrolysis is monitored by chemiluminescence decrease after incubation with PON enzyme
-
-
?
9-(4-chlorophenoxycarbonyl)-10-methylacridinium triflate + H2O
?
synthesis method, overview. The assay is based on the PON1-mediated hydrolysis of an acridinium ester, and the hydrolysis is monitored by chemiluminescence decrease after incubation with PON enzyme
-
-
?
9-(4-methylphenoxycarbonyl)-10-methylacridinium triflate + H2O
?
synthesis method, overview. The assay is based on the PON1-mediated hydrolysis of an acridinium ester, and the hydrolysis is monitored by chemiluminescence decrease after incubation with PON enzyme
-
-
?
9-(4-tert-butylphenoxycarbonyl)-10-methylacridinium triflate + H2O
?
synthesis method, overview. The assay is based on the PON1-mediated hydrolysis of an acridinium ester, and the hydrolysis is monitored by chemiluminescence decrease after incubation with PON enzyme
-
-
?
9-(phenyloxycarbonyl)-10-methylacridinium triflate + H2O
?
synthesis method, overview. The assay is based on the PON1-mediated hydrolysis of an acridinium ester, and the hydrolysis is monitored by chemiluminescence decrease after incubation with PON enzyme
-
-
?
benzyl acetate + H2O
?
-
-
-
?
bis(1-methylethyl) 2-oxo-4-(trifluoromethyl)-2H-chromen-7-yl phosphate + H2O
dipropan-2-yl phosphate + 7-hydroxy-4-(trifluoromethyl)-2H-1-benzopyran-2-one
-
-
-
?
bis(1-methylethyl) 4-methyl-2-oxo-2H-chromen-7-yl phosphate + H2O
dipropan-2-yl phosphate + 7-hydroxy-4-methyl-2H-1-benzopyran-2-one
-
-
-
?
chlorpyrifos + H2O
3,5,6-trichloro-pyridin-2-ol + diethyl thiophosphate
-
-
-
?
chlorpyrifos + H2O
?
-
-
-
?
chlorpyrifos oxon + H2O
3,5,6-trichloro-pyridin-2-ol + diethyl phosphate
-
-
-
?
chlorpyrifos oxon + H2O
?
-
-
-
?
chlorpyrifos oxon + H2O
diethyl phosphate + 3,5,6-trichloropyridin-2-ol
chlorpyrifos-oxon + H2O
3,5,6-trichloro-2-pyridinol + diethyl phosphate
-
-
-
?
chlortion + H2O
?
chlorthion is O,O-dimethyl O-(3-chloro-4-nitrophenyl) thionophosphate
-
-
?
cyclohexyl 2-oxo-4-(trifluoromethyl)-2H-chromen-7-yl methylphosphonate + H2O
cyclohexyl methylphosphonate + 7-hydroxy-4-(trifluoromethyl)-2H-1-benzopyran-2-one
-
-
-
?
cyclohexyl 4-methyl-2-oxo-2H-chromen-7-yl methylphosphonate + H2O
cyclohexyl methylphosphonate + 7-hydroxy-4-methyl-2H-1-benzopyran-2-one
-
-
-
?
cyclosarin + H2O
?
-
-
-
?
diazoxon + H2O
2-isopropyl-6-methyl-pyrimidin-4-ol + diethyl phosphate
diethyl (3,5,6-trichloropyridin-2-yl) phosphate + H2O
?
i.e. chlorpyrifos-oxon or CPO
-
-
?
diethyl 2-oxo-4-(trifluoromethyl)-2H-chromen-7-yl phosphate + H2O
diethyl phosphate + 7-hydroxy-4-(trifluoromethyl)-2H-1-benzopyran-2-one
-
-
-
?
diethyl 4-chlorophenyl phosphate + H2O
4-chlorophenol + diethyl phosphate
-
-
-
?
diethyl-paraoxon + H2O
diethyl phosphate + 4-nitrophenol
diisopropyl fluorophosphate + H2O
?
-
-
-
?
diisopropyl fluorophosphate + H2O
diisopropyl phosphate + fluoride
diisopropyl fluorophosphate + H2O
isopropanol + ?
-
-
-
?
dimethyl 2-oxo-4-(trifluoromethyl)-2H-chromen-7-yl phosphate + H2O
dimethyl phosphate + 7-hydroxy-4-(trifluoromethyl)-2H-1-benzopyran-2-one
-
-
-
?
dimethyl 4-methyl-2-oxo-2H-chromen-7-yl phosphate + H2O
?
-
-
-
?
dimethyl-paraoxon + H2O
dimethyl phosphate + 4-nitrophenol
-
-
-
?
ethyl 2-oxo-4-(trifluoromethyl)-2H-chromen-7-yl methylphosphonate + H2O
ethyl methylphosphonate + 7-hydroxy-4-(trifluoromethyl)-2H-1-benzopyran-2-one
-
-
-
?
ethyl 4-methyl-2-oxo-2H-chromen-7-yl methylphosphonate + H2O
ethyl methylphosphonate + 7-hydroxy-4-methyl-2H-1-benzopyran-2-one
-
-
-
?
ethyl acetate + H2O
?
-
-
-
?
methylphosphonic acid + H2O
?
i.e. MPA, according to the C-P lyase pathway, methylphosphonic acid decomposition by the enzyme is expected to yield methane as a product. But no methane is detected during the reaction process. Methanol cannot be detected either during the MPA decomposition reaction, as well as formaldehyde, but formic acid is identified in the reaction mixture
-
-
?
N-[2-[ethoxy(methyl)phosphoryl]sulfanethyl]-N-propan-2-ylpropan-2-amine + H2O
S-[2-(diisopropylamino)ethyl]-methylphosphonothioic acid + ethanol
the enzyme shows only minimal activity against the nerve agent VX
-
-
?
O,O'-(diisobutyl)methylphosphonate + H2O
?
-
-
-
?
O,O-dimethyl O-(4-methyl-2-oxo-2H-chromen-7-yl) thiophosphate + H2O
?
-
-
-
?
O,O-dimethyl O-[2-oxo-4-(trifluoromethyl)-2H-chromen-7-yl] thiophosphate + H2O
?
-
-
-
?
O-(isobutyl)methylphosphonate + H2O
?
very low activity
-
-
?
O-ethyl O-4-nitrophenyl phenylphosphonothioate + H2O
?
-
-
-
?
O-ethyl S-2-diisopropylaminoethyl methylphosphonothiolate + H2O
?
-
-
-
?
paraoxon + H2O
4-nitrophenol + diethyl phosphate
paraoxon + H2O
4-nitrophenol + diethylphosphate
-
-
-
?
paraoxon + H2O
diethyl phosphate + 4-nitrophenol
-
-
-
?
paraoxon + H2O
diethylphosphate + 4-nitrophenol
parathion + H2O
diethyl thiophosphate + 4-nitrophenol
-
-
-
?
pentafluorophenyl diethyl phosphate + H2O
?
-
-
-
?
pentafluorophenyl diethyl phosphate + H2O
pentafluorophenol + diethyl phosphate
-
-
-
?
phenyl acetate + H2O
phenol + acetate
sarin + H2O
methyl-phosphonic acid monofluoride + isopropyl alcohol
PON1 hydrolyzes sarin more effectively than paraoxon, sarin is o-isopropyl methylphosphonofluoridate
-
-
?
soman + H2O
methylphosphonofluoride acid + 3,3-dimethylbutan-2-ol
PON1 hydrolyzes soman more effectively than paraoxon, soman is o-pinacolyl methylphosphonofluoridate
-
-
?
1-methylethyl 4-nitrophenyl (1-methylpropyl)phosphonate + H2O
4-nitrophenol + 1-methylethyl hydrogen (1-methylpropyl)phosphonate
low activity
-
-
?
1-methylethyl 4-nitrophenyl methylphosphonate + H2O
4-nitrophenol + 1-methylethyl hydrogen methylphosphonate
-
-
-
?
1-methylpropyl 4-nitrophenyl methylphosphonate + H2O
4-nitrophenol + 1-methylpropyl hydrogen methylphosphonate
best substrate
-
-
?
1-palmitoyl-2-(5-oxo)valeroyl-sn-glycero-3-phosphocholine + H2O
lysophosphatidylcholine + ?
-
-
-
?
1-palmitoyl-2-(9-oxo)nonanoyl-sn-glycero-3-phosphocholine + H2O
?
-
-
-
-
?
4-acetylphenyl (2R)-3,3-dimethylbutan-2-yl (R)-methylphosphonate + H2O
4-acetylphenol + (2R)-3,3-dimethylbutan-2-yl (R)-methylphosphonate
-
-
-
-
?
4-acetylphenyl (2R)-3,3-dimethylbutan-2-yl (S)-methylphosphonate + H2O
4-acetylphenol + (2R)-3,3-dimethylbutan-2-yl (S)-methylphosphonate
-
-
-
-
?
4-acetylphenyl (2S)-3,3-dimethylbutan-2-yl (R)-methylphosphonate + H2O
4-acetylphenol + 4-acetylphenol + (2S)-3,3-dimethylbutan-2-yl (R)-methylphosphonate
-
-
-
-
?
4-acetylphenyl (2S)-3,3-dimethylbutan-2-yl (S)-methylphosphonate + H2O
4-acetylphenol + (2S)-3,3-dimethylbutan-2-yl (S)-methylphosphonate
-
-
-
-
?
4-acetylphenyl 2-methylpropyl (R)-methylphosphonate + H2O
4-acetylphenol + 2-methylpropyl (R)-methylphosphonate
-
-
-
-
?
4-acetylphenyl 2-methylpropyl (S)-methylphosphonate + H2O
4-acetylphenol + 2-methylpropyl (S)-methylphosphonate
-
-
-
-
?
4-acetylphenyl cyclohexyl (R)-methylphosphonate + H2O
4-acetylphenol + cyclohexyl (R)-methylphosphonate
-
-
-
-
?
4-acetylphenyl cyclohexyl (S)-methylphosphonate + H2O
4-acetylphenol + cyclohexyl (S)-methylphosphonate
-
-
-
-
?
4-acetylphenyl ethyl (R)-methylphosphonate + H2O
4-acetylphenol + ethyl (R)-methylphosphonate
-
-
-
-
?
4-acetylphenyl ethyl (S)-methylphosphonate + H2O
4-acetylphenol + ethyl (S)-methylphosphonate
-
-
-
-
?
4-acetylphenyl propan-2-yl (R)-methylphosphonate + H2O
4-acetylphenol + propan-2-yl (R)-methylphosphonate
-
-
-
-
?
4-acetylphenyl propan-2-yl (S)-methylphosphonate + H2O
4-acetylphenol + propan-2-yl (S)-methylphosphonate
-
-
-
-
?
4-nitrophenyl phenyl methylphosphonate + H2O
4-nitrophenol + phenyl hydrogen methylphosphonate
-
-
-
?
4-nitrophenyl phosphate + H2O
4-nitrophenol + phosphate
-
-
-
-
?
4-nitrophenyl propyl methylphosphonate + H2O
4-nitrophenol + propyl hydrogen methylphosphonate
best substrate
-
-
?
7-diethylphospho-6,8-difluor-4-methylumbelliferyl + H2O
diethylphosphate + 6,8-difluor-4-methylumbelliferol
-
high level of hydrolysis of the fluorogenic substrate, fluorescence assay method optimization
-
-
?
chlorpyrifos-oxon + H2O
?
-
-
-
-
?
chlorpyrifosoxon + H2O
3,5,6-trichloro-pyridin-2-ol + diethyl phosphate
-
-
-
?
chlorpyriphosoxon + H2O
?
-
-
-
-
?
CVX + H2O
?
-
i.e. diethylamino-ethyl-O-butyl methylphosphonothioate
-
-
?
cyclosarin + H2O
?
-
-
-
-
?
cyclosarin + H2O
methyl-phosphonic acid monofluoride + cyclohexanol
-
-
-
-
?
diazoxon + H2O
6-methyl-2-(1-methylethyl)pyrimidin-4-ol + diethyl phosphate
-
-
-
-
ir
diazoxon + H2O
?
-
-
-
-
?
diethyl 4-nitrophenyl phosphate + H2O
4-nitrophenol + diethyl hydrogen phosphate
low activity
-
-
?
diethyl 4-nitrophenyl phosphate + H2O
4-nitrophenol + diethyl phosphate
diethyl 4-nitrophenyl phosphate + H2O
p-nitrophenol + diethyl phosphate
-
-
-
-
?
diethyl paraoxon + H2O
?
-
-
-
-
?
diisopropyl fluorophosphate + H2O
?
diisopropylfluorophosphate + H2O
?
-
-
-
?
dimethyl paraoxon + H2O
?
-
-
-
-
?
ethyl 1-methylethyl 4-nitrophenyl phosphate + H2O
4-nitrophenol + ethyl 1-methylethyl hydrogen phosphate
low activity
-
-
?
ethyl 4-nitrophenyl (1-methylpropyl)phosphonate + H2O
4-nitrophenol + ethyl hydrogen (1-methylpropyl)phosphonate
-
-
-
?
ethyl 4-nitrophenyl methylphosphonate + H2O
4-nitrophenol + ethyl hydrogen methylphosphonate
low activity
-
-
?
ethyl paraoxon + H2O
4-nitrophenol + diethyl phosphate
-
-
-
?
fenitroxon + H2O
?
-
-
-
-
?
methyl paraoxon + H2O
4-nitrophenol + dimethyl phosphate
-
-
-
-
?
methyl paraoxon + H2O
4-nitrophenol + dimethylphosphate
-
the enzyme reaction also produces two protons, which lower the pH and establish a steady pH gradient
-
-
?
methyl parathion + H2O
dimethyl thiophosphate + 4-nitrophenol
-
-
-
-
?
mono(diethylphosphoryl)obidoxime + H2O
diethyl hydrogenphosphate + obidoxime
-
substrate is a potent inhibitor of human acetylcholinesterase
-
-
?
nitrophenyl isopropyl methylphosphonate + H2O
nitrophenol + propan-2-yl hydrogen methylphosphonate
-
a series of substituted phenoxyalkyl pyridinium oximes enhance the degradation of surrogates of sarin (i.e. nitrophenyl isopropyl methylphosphonate, NIMP) and VX (i.e. nitrophenyl ethyl methylphosphonate, NEMP). Neither NIMP nor NEMP is hydrolyzed effectively by paraoxonase PON1 if one of these oximes is absent. In the presence of eight novel oximes, PON1-mediated degradation of both surrogates occurs
-
-
?
O,O-diethyl O-4-nitrophenyl phosphate + H2O
4-nitrophenol + diethyl phosphate
-
-
-
-
?
O-ethyl S-(2-diisopropylaminoethyl) methylphosphonothioate + H2O
?
-
i.e. VX, a highly toxic organophosphorus nerve agent, stereospecific hydrolysis
-
-
?
O-ethyl-S-[2-(diisopropylamino)ethyl]-methylphosphonothioic acid + H2O
S-[2-(diisopropylamino)ethyl]-methylphosphonothioic acid + ethanol
-
hydrolysis is exclusively preferential for the P+ isomer. Glycosylation state of PON1 does not affect substrate stereoselectivity
-
-
?
O-ethyl-S-[2-(diisopropylamino)ethyl]methylphosphonothioate + H2O
S-[2-(diisopropylamino)ethyl]-methylphosphonothioic acid + ethanol
-
O-ethyl-S-[2-(diisopropylamino)ethyl]methylphosphonothiate's lone oxygen atom has a strong preference for forming a direct electrostatic interaction with PON1's active site calcium ion. Key residues, which interact with VX are E53, H115, N168, F222, N224, L240, D269, I291, F292, and V346. Residue D183 located in PON1's active site may act as a proton donor or accepter during hydrolysis. PON1's flexible loop region acts as a gatekeeper to the active site residues required for binding VX
-
-
?
O-isobutyl-S-[2-(diethylamino)ethyl]methylphosphonothioic acid + H2O
?
-
hydrolysis is exclusively preferential for the P+ isomer. Glycosylation state of PON1 does not affect substrate stereoselectivity
-
-
?
paraoxon + H2O
4-nitrophenol + diethyl phosphate
paraoxon + H2O
4-nitrophenol + diethylphosphate
-
-
-
-
?
paraoxon + H2O
diethyl phosphate + 4-nitrophenol
-
paraoxon is diethyl 4-nitrophenyl phosphate
-
-
?
paraoxon + H2O
diethylphosphate + 4-nitrophenol
paraoxon ethylene + H2O
4-nitrophenol + diethyl phosphate
-
-
-
-
?
phenyl acetate + H2O
phenol + acetate
phosphatidylcholine isoprostane + H2O
?
-
-
-
-
?
russian VX + H2O
methyl-phosphonothioic acid S-(2-diethylamino-ethyl) ester + 2-methylpropanol
-
-
-
-
?
sarin + H2O
methyl-phosphonic acid monofluoride + isopropyl alcohol
-
-
-
-
?
sarin + H2O
methylphosphonofluoride acid + ?
-
a highly toxic organophosphorus nerve agent, stereospecific hydrolysis
-
-
?
soman + H2O
methyl-phosphonic acid monofluoride + 1,2,2-trimethylpropanol
-
-
-
-
?
soman + H2O
methylphosphonofluoride acid + 3,3-dimethylbutan-2-ol
-
i.e. pinacolyl methylphosphonofluoridate, a highly toxic organophosphorus nerve agent, stereospecific hydrolysis
-
-
?
tabun + H2O
cyanophosphonic acid dimethylamide + ethanol
-
-
-
-
?
VX + H2O
S-[2-(diisopropylamino)ethyl]-methylphosphonothioic acid + ethanol
-
-
-
-
?
additional information
?
-
chlorpyrifos oxon + H2O
diethyl phosphate + 3,5,6-trichloropyridin-2-ol
-
-
-
?
chlorpyrifos oxon + H2O
diethyl phosphate + 3,5,6-trichloropyridin-2-ol
i.e. CPO, a metabolite of chlorpyrifos that is used as a pesticide in agriculture industry
-
-
?
diazoxon + H2O
2-isopropyl-6-methyl-pyrimidin-4-ol + diethyl phosphate
-
-
-
?
diazoxon + H2O
2-isopropyl-6-methyl-pyrimidin-4-ol + diethyl phosphate
the homozygote wild type enzyme (QQ phenotype of Q192R) hydrolyzes diaxozon more rapidly than paraoxon
-
-
?
diazoxon + H2O
2-isopropyl-6-methyl-pyrimidin-4-ol + diethyl phosphate
the homozygote wild type enzyme shows highest activity towards diazoxon
-
-
?
diazoxon + H2O
?
-
-
-
?
diazoxon + H2O
?
highest activity with diazoxon
-
-
?
diethyl-paraoxon + H2O
diethyl phosphate + 4-nitrophenol
-
-
-
?
diethyl-paraoxon + H2O
diethyl phosphate + 4-nitrophenol
-
-
-
?
diethyl-paraoxon + H2O
diethyl phosphate + 4-nitrophenol
-
-
-
-
?
diethyl-paraoxon + H2O
diethyl phosphate + 4-nitrophenol
-
-
-
?
diisopropyl fluorophosphate + H2O
diisopropyl phosphate + fluoride
reaction of EC 3.1.8.2
-
-
?
diisopropyl fluorophosphate + H2O
diisopropyl phosphate + fluoride
reaction of EC 3.1.8.2, highly toxic structural analogue of G-class type of nerve agents
-
-
?
paraoxon + H2O
4-nitrophenol + diethyl phosphate
-
-
-
?
paraoxon + H2O
4-nitrophenol + diethyl phosphate
-
-
-
-
?
paraoxon + H2O
4-nitrophenol + diethyl phosphate
-
-
-
?
paraoxon + H2O
4-nitrophenol + diethyl phosphate
-
-
-
?
paraoxon + H2O
4-nitrophenol + diethyl phosphate
-
-
-
?
paraoxon + H2O
4-nitrophenol + diethyl phosphate
-
-
-
-
?
paraoxon + H2O
4-nitrophenol + diethyl phosphate
-
-
-
?
paraoxon + H2O
4-nitrophenol + diethyl phosphate
-
-
-
-
?
paraoxon + H2O
4-nitrophenol + diethyl phosphate
-
-
-
?
paraoxon + H2O
4-nitrophenol + diethyl phosphate
enzyme variant Q192: 1.3% of the activity with phenyl acetate (see EC 3.1.1.2), enzyme variant R192: 1% of the activity with phenyl acetate (see EC 3.1.1.2). Enzyme protein also shows activities of EC 3.1.1.25 and EC 3.1.1.2
-
-
?
paraoxon + H2O
diethylphosphate + 4-nitrophenol
-
-
-
?
paraoxon + H2O
diethylphosphate + 4-nitrophenol
-
-
-
?
paraoxon + H2O
diethylphosphate + 4-nitrophenol
-
-
-
?
paraoxon + H2O
diethylphosphate + 4-nitrophenol
-
-
-
-
?
paraoxon + H2O
diethylphosphate + 4-nitrophenol
-
-
-
?
paraoxon + H2O
diethylphosphate + 4-nitrophenol
-
-
-
-
?
paraoxon + H2O
diethylphosphate + 4-nitrophenol
-
-
-
?
paraoxon + H2O
diethylphosphate + 4-nitrophenol
-
-
-
-
?
paraoxon + H2O
diethylphosphate + 4-nitrophenol
-
-
-
?
paraoxon + H2O
diethylphosphate + 4-nitrophenol
-
-
-
-
?
paraoxon + H2O
diethylphosphate + 4-nitrophenol
-
-
-
?
paraoxon + H2O
diethylphosphate + 4-nitrophenol
-
-
-
-
?
paraoxon + H2O
diethylphosphate + 4-nitrophenol
-
-
-
?
paraoxon + H2O
diethylphosphate + 4-nitrophenol
-
-
-
-
?
paraoxon + H2O
diethylphosphate + 4-nitrophenol
-
-
-
?
paraoxon + H2O
diethylphosphate + 4-nitrophenol
-
-
-
-
?
paraoxon + H2O
diethylphosphate + 4-nitrophenol
-
-
-
?
paraoxon + H2O
diethylphosphate + 4-nitrophenol
highest activity
-
-
?
paraoxon + H2O
diethylphosphate + 4-nitrophenol
higher activity towards paraoxon than towards phenyl acetate
-
-
?
paraoxon + H2O
diethylphosphate + 4-nitrophenol
paraoxonase activity of PON1 is polymorphism dependent
-
-
?
paraoxon + H2O
diethylphosphate + 4-nitrophenol
PON1 activity determined towards the synthetic compounds paraoxon and phenyl acetate reflects no association with markers of oxidative stress
-
-
?
paraoxon + H2O
diethylphosphate + 4-nitrophenol
the homozygote RR phenotype of Q192R shows highest activity towards paraoxon
-
-
?
phenyl acetate + H2O
phenol + acetate
-
-
-
?
phenyl acetate + H2O
phenol + acetate
arylesterase activity
-
-
?
sarin + H2O
?
-
-
-
?
soman + H2O
?
-
-
-
?
SP-CMP + H2O
?
SP-CMP is the toxic SP enantiomer of a cyclosarin surrogate in which the fluoride leaving group is replaced by a coumarin derivative
-
-
?
SP-CMP + H2O
?
SP-CMP is the toxic SP enantiomer of a GF surrogate in which the fluoride leaving group is replaced by a coumarin derivative
-
-
?
diethyl 4-nitrophenyl phosphate + H2O
4-nitrophenol + diethyl phosphate
-
-
-
?
diethyl 4-nitrophenyl phosphate + H2O
4-nitrophenol + diethyl phosphate
-
-
-
-
?
diisopropyl fluorophosphate + H2O
?
-
-
-
-
?
diisopropyl fluorophosphate + H2O
?
-
high concentration of purified human serum paraoxonase 1 (about 0.075 mg) is required to hydrolyze 0.002 mM diisopropyl fluorophosphates
-
-
?
paraoxon + H2O
4-nitrophenol + diethyl phosphate
-
-
652704, 664153, 665987, 702421, 707155, 707214, 708095, 709262, 709264, 709291, 709755, 714112, 714893, 714895, 715738, 715744, 716957, 728992, 750345, 750484, 750511, 752173 -
-
?
paraoxon + H2O
4-nitrophenol + diethyl phosphate
-
-
-
-
ir
paraoxon + H2O
4-nitrophenol + diethyl phosphate
-
-
-
?
paraoxon + H2O
4-nitrophenol + diethyl phosphate
-
-
-
?
paraoxon + H2O
4-nitrophenol + diethyl phosphate
-
best substrate
-
-
?
paraoxon + H2O
4-nitrophenol + diethyl phosphate
-
human serum paraoxonase/arylesterase is an esterase with broad substrate specificity. It occurs in two genetically determined allozymic forms, type A and type B. These allozymes are the products of two allelic genes located at the paraoxonase locus on chromosome 7, which is closely linked to the gene for cystic fibrosis. Paraoxonase activity of the B type isozyme is considerably higher and stimulated more by 1 M NaCl than A-type paraoxonase. The ratio of paraoxonase activity to arylesterase activity of the B-isozyme is about 8, and that of the A isozyme about 1
-
-
?
paraoxon + H2O
4-nitrophenol + diethyl phosphate
-
i.e. O,O'-diethyl-4-nitrophenyl phosphothioate
-
-
?
paraoxon + H2O
diethylphosphate + 4-nitrophenol
-
-
35205, 35210, 35218, 35219, 646500, 646504, 646507, 664153, 677411, 677570, 677884, 678489, 693321 -
-
?
paraoxon + H2O
diethylphosphate + 4-nitrophenol
-
paraoxonase and arylesterase activities are significantly lower in a Helicobacter pylori positive group than in a Helicobacter pylori negative group, overview
-
-
?
paraoxon + H2O
diethylphosphate + 4-nitrophenol
-
i.e. diethyl-4-nitrophenylphosphate
-
-
?
paraoxon + H2O
diethylphosphate + 4-nitrophenol
-
A-type paraoxonase shows 0.06% of the activity with phenyl acetate, B-type paraoxonase shows 2.5% of the activity with phenyl acetate
-
-
?
paraoxon + H2O
diethylphosphate + 4-nitrophenol
-
the enzyme exists in two genetically determined allozymic forms, and these A and B allozymes possess both paraoxonase and arylesterase activities. B-type esterase has relatively higher paraoxonase activity and is stimulated to a greater degree by 1 M NaCl than the A allozyme
-
-
?
phenyl acetate + H2O
phenol + acetate
-
-
-
-
?
phenyl acetate + H2O
phenol + acetate
-
-
-
?
sarin + H2O
?
-
-
-
-
?
sarin + H2O
?
-
efficient hydrolysis of sarin (11 nM) is observed with about 0.08-0.25 units of paraoxonase 1
-
-
?
soman + H2O
?
-
-
-
-
?
soman + H2O
?
-
efficient hydrolysis of soman (3 nM) is observed with about 0.08-0.25 units of paraoxonase 1
-
-
?
tabun + H2O
?
-
-
-
-
?
tabun + H2O
?
-
efficient hydrolysis of tabun (100 nM) is observed with about 0.025-0.04 units of paraoxonase 1. Tabun hydrolysis with paraoxonase 1 is about 30-60times and about 200-260times more efficient than that with sarin and soman, respectively
-
-
?
VR + H2O
?
-
-
-
-
?
VR + H2O
?
-
i.e. diethylamino-ethyl-O-isobutyl methylphosphonothioate
-
-
?
VX + H2O
?
-
-
-
-
?
VX + H2O
?
-
i.e. diisopropylamino-ethyl-O-ethyl methylphosphonothioate
-
-
?
additional information
?
-
the serum paraoxonase family contains detoxifying and anti-atherosclerotic enzymes
-
-
?
additional information
?
-
the enzyme associates to HDL in the blood stream
-
-
?
additional information
?
-
polymorphisms allele frequency in relation to exposure of individuals to organophosphates, overview
-
-
?
additional information
?
-
-
polymorphisms allele frequency in relation to exposure of individuals to organophosphates, overview
-
-
?
additional information
?
-
PON1 hydrolyses esters, including organophosphates and lactones, and exhibits anti-atherogenic properties, the enzyme is associated to high-density-lipoprotein, bound together with the human phosphate binding protein
-
-
?
additional information
?
-
PON1 hydrolyzes organophosphates, such as paraoxon, aromatic esters, for instance, phenyl acetate, and also lipid peroxidation products, and reduces the accumulation of them, PON1 prevents the acceleration of atherosclerosis, exhibits antioxidant ability, and assumes an antiatherogenic property. Negative correlation between the activity of PON1 and the level of lipid hydroperoxides in the rheumatoid arthritis patient group, overview
-
-
?
additional information
?
-
PON1 is a lipolactonase that associates with HDL-apolipoprotein A-I and thereby plays a role in the prevention of atherosclerosis
-
-
?
additional information
?
-
-
PON1 is a lipolactonase that associates with HDL-apolipoprotein A-I and thereby plays a role in the prevention of atherosclerosis
-
-
?
additional information
?
-
PON1 is not able to prevent macrophage oxidative stress, however, is able to retard macrophage-induced low-density lipoprotein oxidation
-
-
?
additional information
?
-
PON1 plays a key role in the protection of low density lipoproteins and high density lipoproteins from oxidation by hydrolyzing activated phospholipids and lipid peroxide products
-
-
?
additional information
?
-
-
PON1 plays a key role in the protection of low density lipoproteins and high density lipoproteins from oxidation by hydrolyzing activated phospholipids and lipid peroxide products
-
-
?
additional information
?
-
the active site of PON1 is characterized by two distinct binding regions, the hydrophobic binding site for arylesters/lactones and the paraoxon binding site for phosphotriesters
-
-
?
additional information
?
-
-
the active site of PON1 is characterized by two distinct binding regions, the hydrophobic binding site for arylesters/lactones and the paraoxon binding site for phosphotriesters
-
-
?
additional information
?
-
the enzyme carried by high-density lipoprotein, exerts a protective effect against oxidative damage of cells and lipoproteins, modulating the susceptibility of high-density lipoprotein to atherogenic modifications and has an anti-inflammatory role, low PON1 activity is a risk factor for cardiovascular disease
-
-
?
additional information
?
-
the enzyme is located on high-density lipoprotein and prevents low-density-lipoprotein and high-density-lipoprotein oxidation both in vivo and in vitro through hydrolysis of lipid peroxides, the risk of ischemic stroke is related to the genotype of PON1 192RQ polymorphisms, overview
-
-
?
additional information
?
-
human paraoxonase 1 (h-PON1) can hydrolyze a variety of substrates. Interaction of recombinant PON1 proteins with lactones, overview
-
-
?
additional information
?
-
-
human paraoxonase 1 (h-PON1) can hydrolyze a variety of substrates. Interaction of recombinant PON1 proteins with lactones, overview
-
-
?
additional information
?
-
human PON1 is a calcium-dependent promiscuous enzyme (phosphotriesterase, arylesterase and lactonase) with a wide range of substrates. Human PON1 is capable of hydrolyzing a broad range of organophosphorus compounds, including paraoxon, diisopropylfluorophosphate (DFP) and nerve agents such as sarin, soman and VX
-
-
?
additional information
?
-
PON1 shows very good adaptability in assay development with different substrates, PON1 substrate exhibit many degrees of freedom in docking simulations. The relative chemiluminescent efficiency for the five acridinium esters ranks as the following descreasing order: unsubstituted, 2,4-dimethylphenoxy-, 4-methylphenoxy-, 4-tertbutylphenoxy-, and chloro-acridinium ester. Selfhydrolysis of the five acridinium esters in Tris-HCl buffer, at pH 7.5 and 25°C is insignificant during 22 min, but between 1.03% and 27.17% after 12 weeks
-
-
?
additional information
?
-
-
the enzyme is also active with substrates of EC 3.1.1.81, quorum-quenching N-acyl-homoserine lactonase, and EC 3.1.8.2, diisopropyl-fluorophosphatase, hydrolyzing diisopropyl-fluorophosphates and phosphorus-halide and phosphorus-cyanide bonds in organophosphorus compounds. Measurement of N-oxodecanoyl-DL-homoserine lactone (3O-C10AHL)-hydrolyzing activity (EC 3.1.1.81) of recombinant h-PON1 enzymes is determined by using a recombinant quorum-sensing reporter Escherichia coli strain
-
-
?
additional information
?
-
the enzyme is also active with substrates of EC 3.1.1.81, quorum-quenching N-acyl-homoserine lactonase, and EC 3.1.8.2, diisopropyl-fluorophosphatase, hydrolyzing diisopropyl-fluorophosphates and phosphorus-halide and phosphorus-cyanide bonds in organophosphorus compounds. Measurement of N-oxodecanoyl-DL-homoserine lactone (3O-C10AHL)-hydrolyzing activity (EC 3.1.1.81) of recombinant h-PON1 enzymes is determined by using a recombinant quorum-sensing reporter Escherichia coli strain
-
-
?
additional information
?
-
the recombinant His6-tagged organophosphorus hydrolase (His6-OPH) shows catalytic activity in hydrolytic reactions with methylphosphonic acid (MPA) monoesters and diesters being decomposition products of R-VX nerve agent derivative (O-ethyl-S-(2-diisopropylaminoethyl)methylphosphonothiolate, i.e. VX), analysis of the mechanism of C-P bond cleavage in methylphosphonic acid by His6-OPH, overview. The recombinant enzyme His6-OPH is capable of degrading the key organophosphorus components of reaction masses (RMs) that are produced by chemical detoxification of R-VX, the RMs are multisubstrate mixtures for this enzyme, R-VX decomposition scheme. GC-MS analysis of phosphonates and methane
-
-
?
additional information
?
-
-
isozyme PON2 has antioxidant properties, prevents low density lipoprotein lipid peroxidation and reverses the oxidation of mildly oxidized low density lipoproteins
-
-
?
additional information
?
-
-
PON1 is involved in metabolism of oxidized lipid compounds
-
-
?
additional information
?
-
-
polymorphism of enzyme and implications
-
-
?
additional information
?
-
-
isozyme PON1 is effective at reducing the activity of phospholipid oxidation products
-
-
?
additional information
?
-
-
the enzyme PON2 has antioxidant properties, prevents LDL lipid peroxidation, reverses the oxidation of mildly oxidized LDL, and inhibits the ability of mildly oxidized LDL to induce monocyte chemotaxis
-
?
additional information
?
-
-
HDL-associated enzyme is a cardio- and vasoprotective enzyme
-
-
?
additional information
?
-
-
the enzyme associated to high-density lipoproteins HDL exhibits antioxidant function of particular physiological relevance, mechanism, compositional fluctuations of HDL effects the influence of the enzyme on cardiovascular risks, overview, PON1 content is reduced in human ApoAI deficiency disease
-
-
?
additional information
?
-
-
the enzyme efficiently hydrolyzes organophosphorus nerve agents
-
-
?
additional information
?
-
-
the enzyme is important in detoxification of organophosphorus compounds, structure and applications of organophosphorus compounds, clinical evidence of PON1, overview
-
-
?
additional information
?
-
-
enzyme-HDL complex: interaction and structure analysis
-
-
?
additional information
?
-
-
no activity with dimefox, parathion, methyl parathion, and diisopropyl fluorophosphate, assay method evaluation of analogues with fluorescent leaving groups for screening and selection of the enzyme that efficiently hydrolyzes organophosphorus nerve agents, overview
-
-
?
additional information
?
-
-
PON1 has a protective role e.g. against organophosphorous poisoning, but also against vascular diseases, PON1 has an anti-atherogenic activity
-
-
?
additional information
?
-
-
PON1 is a high-density lipoprotein-associated enzyme capable of hydrolyzing diverse substrates from organophosphate toxins to oxidized phospholipids, PON1 is linked with both the prevention of organophosphate poisoning and inhibition of atherosclerosis initiated by oxidatively modified low-density lipoprotein, overview, phenotypic distribution of the enzyme in individuals of both sexes and different age, overview
-
-
?
additional information
?
-
-
the enzyme depends on high-density lipoprotein HDL as carrier and site of action, PON1 acts as an antioxidant preventing low-density lipoprotein peroxidation, overview
-
-
?
additional information
?
-
-
PON1 is a high-density lipoprotein-associated enzyme capable of hydrolyzing diverse substrates from organophosphate toxins to oxidized phospholipids
-
-
?
additional information
?
-
-
PON1 is associated to HDL and human phosphate-binding protein
-
-
?
additional information
?
-
-
residues Phe222 and His115 are important in organophosphorus substrate specificity and catalysis
-
-
?
additional information
?
-
-
high-density lipoprotein-associated paraoxonase possesses peroxidase-like activity that can contribute to the protective effect of paraoxonase against lipoprotein oxidation. The presence of paraoxonase in high-density lipoprotein may thus be a major contributor to the antiatherogenicity of this lipoprotein
-
-
?
additional information
?
-
no activity with chlorpyrifos oxon and diazoxon
-
-
?
additional information
?
-
no activity with chlorpyrifos oxon and diazoxon
-
-
?
additional information
?
-
the overall substrate preference of cAMPP is methylphosphonates > ethylphosphonates >/= organophosphates
-
-
?
additional information
?
-
the enzyme does not hydrolyse 4-nitrophenyl phenyl ethylphosphonate and 1-methylpropyl 4-nitrophenyl ethylphosphonate
-
-
?
additional information
?
-
-
is resistant to chlorpyrifos
-
-
?
additional information
?
-
-
recombinant human paraoxoanase 1 cannot hydrolyze dimethyl paraoxon even at higher concentrations used
-
-
?
additional information
?
-
-
the stereochemical preference of the wild-type enzyme with chemical warfare agents is for the RP enantiomers
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Acromegaly
Serum paraoxonase level and paraoxonase polymorphism in patients with acromegaly.
Acute Coronary Syndrome
Association between serum paraoxonase activity and oxidative stress in acute coronary syndromes.
Acute Coronary Syndrome
Clinical and Genetic Association of Serum Paraoxonase and Arylesterase Activities With Cardiovascular Risk.
Acute Coronary Syndrome
Influence of high-density lipoprotein and paraoxonase-1 on platelet reactivity in patients with acute coronary syndromes receiving clopidogrel therapy.
Acute Coronary Syndrome
Serum arylesterase activity is negatively correlated with inflammatory markers in patients with acute coronary syndromes.
Adrenocortical Hyperfunction
Serum paraoxonase 1 and butyrylcholinesterase in dogs with hyperadrenocorticism.
Alopecia Areata
Evaluation of Serum Paraoxonase, Arylesterase, Prolidase Activities and Oxidative Stress in Patients with Alopecia Areata.
Alopecia Areata
Serum paraoxonase activity and oxidative status in subjects with alopecia areata.
Alzheimer Disease
Association analysis of the paraoxonase-1 gene with Alzheimer's disease.
Alzheimer Disease
Decreased arylesterase activity of paraoxonase-1 (PON-1) might be a common denominator of neuroinflammatory and neurodegenerative diseases.
Alzheimer Disease
Lack of association between Alzheimer's disease and Gln-Arg 192 Q/R polymorphism of the PON-1 gene in an Italian population.
Alzheimer Disease
Paraoxonase 1 192/55 gene polymorphisms in Alzheimer's disease.
Alzheimer Disease
PON-1 and ferroxidase activities in older patients with mild cognitive impairment, late onset Alzheimer's disease or vascular dementia.
Alzheimer Disease
Responsiveness to cholinesterase inhibitors in Alzheimer's disease: a possible role for the 192 Q/R polymorphism of the PON-1 gene.
Alzheimer Disease
Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia.
Alzheimer Disease
Serum paraoxonase activity is associated with variants in the PON gene cluster and risk of Alzheimer disease.
Alzheimer Disease
Serum paraoxonase and arylesterase activities of paraoxonase-1 (PON-1), mild cognitive impairment, and 2-year conversion to dementia: A pilot study.
Anemia
Comparison of serum paraoxonase and arylesterase activities between iron deficiency anemia patients and chronic kidney disease patients with anemia.
Anemia
Paraoxonase activity in athletes with depleted iron stores and iron-deficient erythropoiesis.
Anemia
Paraoxonase and arylesterase activities in children with iron deficiency anemia and vitamin B12 deficiency anemia.
Anemia
Serum paraoxonase 1 activity in patients with iron deficiency anemia.
Anemia, Iron-Deficiency
Comparison of serum paraoxonase and arylesterase activities between iron deficiency anemia patients and chronic kidney disease patients with anemia.
Anemia, Iron-Deficiency
Paraoxonase and arylesterase activities in children with iron deficiency anemia and vitamin B12 deficiency anemia.
Anemia, Iron-Deficiency
Serum paraoxonase 1 activity in patients with iron deficiency anemia.
Anemia, Sickle Cell
Paraoxonases (PON) 1, 2, and 3 Polymorphisms and PON-1 Activities in Patients with Sickle Cell Disease.
Angina Pectoris
Pro-inflammatory Mediators and Oxidative Stress: Therapeutic Markers for Recurrent Angina Pectoris after Coronary Artery Stenting in Elderly Patients.
Angina, Unstable
Gender-specific correlation between plasma myeloperoxidase levels and serum high-density lipoprotein-associated paraoxonase-1 levels in patients with stable and unstable coronary artery disease.
Anthrax
Serum paraoxonase activity and oxidative stress levels in patients with cutaneous anthrax.
Aortic Aneurysm, Abdominal
Identification of novel diagnostic and prognostic biomarkers for abdominal aortic aneurysm.
Arthritis
Suppression of inflammatory arthritis in human serum paraoxonase 1 transgenic mice.
Arthritis, Psoriatic
HDL associated paraoxonase-1 activity correlates with systemic inflammation, disease activity and cardiovascular risk factors in psoriatic disease.
Arthritis, Rheumatoid
Effect of Fish Oil Supplements on Serum Paraoxonase Activity in Female Patients with Rheumatoid Arthritis: A Double-blind Randomized Controlled Trial.
Arthritis, Rheumatoid
PON-1 haplotype (-108C>T, L55M, and Q192R) modulates the serum levels and activity PONase promoting an atherogenic lipid profile in rheumatoid arthritis patients.
Arthritis, Rheumatoid
Serum paraoxonase activity decreases in rheumatoid arthritis.
Arthritis, Rheumatoid
Soy protein, genistein, and daidzein improve serum paraoxonase activity and lipid profiles in rheumatoid arthritis in rats.
aryldialkylphosphatase deficiency
Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: anti-atherogenic role for paraoxonase-2.
aryldialkylphosphatase deficiency
Paraoxonase-2 deficiency enhances Pseudomonas aeruginosa quorum sensing in murine tracheal epithelia.
Asthma
Evaluation of serum paraoxonase and arylesterase activities in subjects with asthma and chronic obstructive lung disease.
Asthma
Relationship of Oxidant and Antioxidant Markers to Asthma Severity in Egyptian Asthmatic Children.
Asthma
[Serum paraoxonase activity, total antioxidant potential and lipid peroxidation products in children with bronchial asthma exacerbation]
Atherosclerosis
A fluorogenic substrate for detection of organophosphatase activity.
Atherosclerosis
Adenovirus-mediated expression of human paraoxonase 3 protects against the progression of atherosclerosis in apolipoprotein E-deficient mice.
Atherosclerosis
Ameliorative effect of statin therapy on oxidative damage in heart tissue of hypercholesterolemic rabbits.
Atherosclerosis
Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients.
Atherosclerosis
Association between human paraoxonase 1 activity and intima-media thickness in subjects under 55 years of age with carotid artery disease.
Atherosclerosis
Association of serum paraoxonase activity with insulin sensitivity and oxidative stress in hyperthyroid and TSH-suppressed nodular goitre patients.
Atherosclerosis
Beyond reduction of atherosclerosis: PON2 provides apoptosis resistance and stabilizes tumor cells.
Atherosclerosis
Carotid intima-media thickness and paraoxonase activity in patients with ankylosing spondylitis.
Atherosclerosis
Clinical and Genetic Association of Serum Paraoxonase and Arylesterase Activities With Cardiovascular Risk.
Atherosclerosis
Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis.
Atherosclerosis
Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice.
Atherosclerosis
Decreased obesity and atherosclerosis in human paraoxonase 3 transgenic mice.
Atherosclerosis
Decreased paraoxonase-2 expression in human carotids during the progression of atherosclerosis.
Atherosclerosis
Effect of levothyroxine replacement therapy on paraoxonase-1 and carotid intima-media thickness in subclinical hypothyroidism.
Atherosclerosis
Effects of Intranasal Estradiol Treatment on Serum Paraoxonase and Lipids in Healthy, Postmenopausal Women.
Atherosclerosis
Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity.
Atherosclerosis
Gene delivery of paraoxonase-1 inhibits neointimal hyperplasia after arterial balloon-injury in rabbits fed a high-fat diet.
Atherosclerosis
Genetic associations and serum paraoxonase levels with atherosclerosis in western Iranian patients.
Atherosclerosis
Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model.
Atherosclerosis
High prevalence of low serum paraoxonase-1 in subjects with coronary artery disease.
Atherosclerosis
Human paraoxonase-1 activity in childhood obesity and its relation to leptin and adiponectin levels.
Atherosclerosis
Hydrolysis of platelet-activating factor by human serum paraoxonase.
Atherosclerosis
In vivo administration of BL-3050: highly stable engineered PON1-HDL complexes.
Atherosclerosis
Interaction between metabolic syndrome and PON1 polymorphisms as a determinant of the risk of coronary artery disease.
Atherosclerosis
Is it just paraoxonase 1 or are other members of the paraoxonase gene family implicated in atherosclerosis?
Atherosclerosis
Lack of association between carotid intima-media thickness and paraoxonase gene polymorphism in non-insulin dependent diabetes mellitus.
Atherosclerosis
Lack of association between serum paraoxonase 1 activities and increased oxidized low-density lipoprotein levels in impaired glucose tolerance and newly diagnosed diabetes mellitus.
Atherosclerosis
Lack of association between the paraoxonase 1 Q/R192 single nucleotide polymorphism and stroke in a Chinese cohort.
Atherosclerosis
Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis.
Atherosclerosis
Non-diabetic metabolic syndrome and obesity do not affect serum paraoxonase and arylesterase activities but do affect oxidative stress and inflammation.
Atherosclerosis
Oxidative Stress Biomarkers and Peripheral Endothelial Dysfunction in Rheumatoid Arthritis: A Monocentric Cross-Sectional Case-Control Study.
Atherosclerosis
p-Cymene Modulate Oxidative Stress and Inflammation in Murine Macrophages: Potential Implication in atherosclerosis.
Atherosclerosis
Paraoxonase activity and genetic polymorphisms in greenhouse workers with long term pesticide exposure.
Atherosclerosis
Paraoxonase activity is reduced by a pro-atherosclerotic diet in rabbits.
Atherosclerosis
Paraoxonase genotype and carotid intima-media thickness in children with familial hypercholesterolemia.
Atherosclerosis
Paraoxonase genotype, LDL-oxidation and carotid atherosclerosis in male life-long smokers.
Atherosclerosis
Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?
Atherosclerosis
Paraoxonase variants relate to 10-year risk in coronary artery disease: impact of a high-density lipoprotein-bound antioxidant in secondary prevention.
Atherosclerosis
Paraoxonase-1 activity in patients with hyperemesis gravidarum.
Atherosclerosis
Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance.
Atherosclerosis
Paraoxonase-1 does not reduce or modify oxidation of phospholipids by peroxynitrite.
Atherosclerosis
Paraoxonase-1: Characteristics and role in atherosclerosis and carotid artery disease.
Atherosclerosis
Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: anti-atherogenic role for paraoxonase-2.
Atherosclerosis
Plasma Paraoxonase-1, Oxidized Low-Density Lipoprotein and Lipid Peroxidation Levels in Gout Patients.
Atherosclerosis
Protectors or Traitors: The Roles of PON2 and PON3 in Atherosclerosis and Cancer.
Atherosclerosis
R-carrying genotypes of serum paraoxonase (PON1) 192 polymorphism and higher activity ratio are related to susceptibility against ischemic stroke.
Atherosclerosis
Role of JNK and c-Jun signaling pathway in regulation of human serum paraoxonase-1 gene transcription by berberine in human HepG2 cells.
Atherosclerosis
Semiautomated method for determination of serum paraoxonase activity using paraoxon as substrate.
Atherosclerosis
Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes.
Atherosclerosis
Serum paraoxonase activity and protein thiols in chronic renal failure patients.
Atherosclerosis
Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins.
Atherosclerosis
Serum paraoxonase level and paraoxonase polymorphism in patients with acromegaly.
Atherosclerosis
Serum paraoxonase-1 activity in women with endometriosis and its relationship with the stage of the disease.
Atherosclerosis
Serum PON-1 Activity but not Q192R Polymorphism is Related to the Extent of Atherosclerosis.
Atherosclerosis
Some indazoles reduced the activity of human serum paraoxonase 1, an antioxidant enzyme: in vitro inhibition and molecular modeling studies.
Atherosclerosis
The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity.
Atherosclerosis
The paraoxonase promoter polymorphism (-107)T>C is not associated with carotid intima-media thickness in Sicilian hypercholesterolemic patients.
Atherosclerosis
Ultrasensitive assay for detection of serum paraoxonase by modulating the growth of fluorescent semiconductor nanoparticles.
Atherosclerosis
[Paraoxonase: its multiple functions and pharmacological regulation].
Breast Neoplasms
Association of Serum Paraoxonase 1 Activities, Polymorphisms and Oxidative Stress in Breast Cancer Patients with Type 2 Diabetes Mellitus.
Breast Neoplasms
Serum paraoxonase and arylesterase can be useful markers to predict neoadjuvant chemotherapy requirement in patients with breast cancer.
Brucellosis
Serum paraoxonase activity, total thiols levels, and oxidative status in patients with acute brucellosis.
Brucellosis
Serum paraoxonase, TAS, TOS and ceruloplasmin in brucellosis.
Carcinogenesis
Assessment of serum paraoxonase and arylesterase activity in patients with endometrial cancer.
Carcinogenesis
Bladder Cancer Chemosensitivity is Affected by Paraoxonase-2 Expression.
Carcinoma
Differential immunohistochemical expression of paraoxonase-2 in actinic keratosis and squamous cell carcinoma.
Carcinoma
Measurement of serum paraoxonase activity and MDA concentrations in patients suffering with oral squamous cell carcinoma.
Carcinoma
Oral squamous cell carcinoma and serum paraoxonase 1.
Carcinoma
Paraoxonase 3 promotes cell proliferation and metastasis by PI3K/Akt in oral squamous cell carcinoma.
Carcinoma
Serum paraoxonase activity and oxidative DNA damage in patients with laryngeal squamous cell carcinoma.
Carcinoma, Hepatocellular
Amphenicol and Macrolide Derived Antibiotics Inhibit Paraoxonase Enzyme Activity in Human Serum and Human Hepatoma Cells (HepG2) in vitro.
Carcinoma, Hepatocellular
Analysis of Serum Paraoxonase 1 Using Mass Spectrometry and Lectin Immunoassay in Patients With Alpha-Fetoprotein Negative Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Diagnosis of AFP-negative early-stage hepatocellular carcinoma using Fuc-PON1.
Carcinoma, Hepatocellular
Dietary polyphenols increase paraoxonase 1 gene expression by an aryl hydrocarbon receptor-dependent mechanism.
Carcinoma, Hepatocellular
Downregulation of paraoxonase 3 contributes to aggressive human hepatocellular carcinoma progression and associates with poor prognosis.
Carcinoma, Hepatocellular
Expression of major HDL-associated antioxidant PON-1 is gender dependent and regulated during inflammation.
Carcinoma, Hepatocellular
Induction of the paraoxonase-1 gene expression by resveratrol.
Carcinoma, Hepatocellular
Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins.
Carcinoma, Hepatocellular
Paraoxonase 3 inhibits cell proliferation and serves as a prognostic predictor in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Serum fucosylated paraoxonase 1 as a potential glycobiomarker for clinical diagnosis of early hepatocellular carcinoma using ELISA Index.
Carcinoma, Hepatocellular
Serum paraoxonase 1 heteroplasmon, a fucosylated, and sialylated glycoprotein in distinguishing early hepatocellular carcinoma from liver cirrhosis patients.
Carcinoma, Ovarian Epithelial
Serum paraoxonase and arylesterase activities in patients with epithelial ovarian cancer.
Carcinoma, Squamous Cell
Differential immunohistochemical expression of paraoxonase-2 in actinic keratosis and squamous cell carcinoma.
Cardiomyopathy, Dilated
Serum paraoxonase activity in patients with ischaemic and nonischaemic dilated cardiomyopathy.
Cardiovascular Diseases
Bovine growth hormone-transgenic mice have major alterations in hepatic expression of metabolic genes.
Cardiovascular Diseases
Concerning the Significance of Paraoxonase-1 and SR-B1 Genes in Atherosclerosis.
Cardiovascular Diseases
Decrease of serum paraoxonase activity in chronic renal failure.
Cardiovascular Diseases
Effects of red wine consumption on serum paraoxonase/arylesterase activities and on lipoprotein oxidizability in healthy-men.
Cardiovascular Diseases
Evaluation of the impacts of antibiotic drugs on PON 1; a major bioscavenger against cardiovascular diseases.
Cardiovascular Diseases
Factors associated to serum paraoxonase 1 activity in patients with cardiovascular disease.
Cardiovascular Diseases
Inverse correlation of serum paraoxonase and homocysteine thiolactonase activities and antioxidant capacity of high-density lipoprotein with the severity of cardiovascular disease in persons with type 2 diabetes mellitus.
Cardiovascular Diseases
Oxidative inactivation of paraoxonase--implications in diabetes mellitus and atherosclerosis.
Cardiovascular Diseases
Paraoxonase 1 R/Q alleles are associated with differential accumulation of saturated versus 20:5n3 fatty acid in human adipose tissue.
Cardiovascular Diseases
Paraoxonase phenotype distribution in a healthy Iranian population.
Cardiovascular Diseases
PON1 concentration and high-density lipoprotein characteristics as cardiovascular biomarkers.
Cardiovascular Diseases
Review of human studies on oxidative damage and antioxidant protection related to cardiovascular diseases.
Cardiovascular Diseases
The combined effect of paraoxonase promoter and coding region polymorphisms on the risk of arterial ischemic stroke among young adults.
Carotid Artery Diseases
Paraoxonase-1 and Symptomatic Status in Carotid Artery Disease.
Carotid Artery Diseases
Paraoxonase-1: Characteristics and role in atherosclerosis and carotid artery disease.
Carotid Artery Diseases
Risk of carotid atherosclerosis is associated with low serum paraoxonase (PON1) activity among arsenic exposed residents in Southwestern Taiwan.
Carotid Artery Diseases
The associations between serum paraoxonase 1 activity and carotid atherosclerosis in renal transplant patients.
Carotid Stenosis
Paraoxonase-1 and Symptomatic Status in Carotid Artery Disease.
Cerebral Hemorrhage
Lack of association between the paraoxonase 1 Q/R192 single nucleotide polymorphism and stroke in a Chinese cohort.
Cerebral Infarction
Human serum paraoxonase gene polymorphisms, Q192R and L55M, are not associated with the risk of cerebral infarction in Chinese Han population.
Cholelithiasis
Response to: Serum paraoxonase and malondialdehyde levels in asymptomatic cholelithiasis.
Cholelithiasis
Serum paraoxonase and malondialdehyde levels in asymptomatic cholelithiasis.
Chorioamnionitis
Prolidase, matrix metalloproteinases 1 and 13 activity, oxidative-antioxidative status as a marker of preterm premature rupture of membranes and chorioamnionitis in maternal vaginal washing fluids.
Colitis
Paraoxonase-1 suppresses experimental colitis via the inhibition of IFN-? production from CD4 T cells.
Colitis, Ulcerative
Paraoxonase-1 and arylesterase levels in patients with ulcerative colitis.
Colitis, Ulcerative
Serum paraoxonase 1 activity and malondialdehyde levels in patients with ulcerative colitis.
Condylomata Acuminata
Determining oxidant and antioxidant status in patients with genital warts.
Coronary Artery Disease
A preliminary study of human paraoxonase and PON 1 L/M55-PON 1 Q/R 192 polymorphisms in Turkish patients with coronary artery disease.
Coronary Artery Disease
Antibodies against N?-homocysteinylated proteins in patients on different methods of renal replacement therapy.
Coronary Artery Disease
Association analysis of PON2 genetic variants with serum paraoxonase activity and systemic lupus erythematosus.
Coronary Artery Disease
Association between paraoxonase activity and lipid levels in patients with premature coronary artery disease.
Coronary Artery Disease
Association of cys 311 ser polymorphism of paraoxonase-2 gene with the risk of coronary artery disease.
Coronary Artery Disease
Association of serum paraoxonase activity and coronary artery calcification.
Coronary Artery Disease
Cardiovascular diseases: oxidative damage and antioxidant protection.
Coronary Artery Disease
Clinical and Genetic Association of Serum Paraoxonase and Arylesterase Activities With Cardiovascular Risk.
Coronary Artery Disease
Coronary artery disease risk factors in patients with schizophrenia: effects of short term antipsychotic treatment.
Coronary Artery Disease
High prevalence of low serum paraoxonase-1 in subjects with coronary artery disease.
Coronary Artery Disease
Low levels of serum paraoxonase activities are characteristic of metabolic syndrome and may influence the metabolic-syndrome-related risk of coronary artery disease.
Coronary Artery Disease
Novel serum paraoxonase activity assays are associated with coronary artery disease.
Coronary Artery Disease
Paraoxonase 3: Structure and Its Role in Pathophysiology of Coronary Artery Disease.
Coronary Artery Disease
Paraoxonase and arylesterase activities in stent restenosis in bare metal stent.
Coronary Artery Disease
PON-1 Activity and Plasma 8-Isoprostane Concentration in Patients with Angiographically Proven Coronary Artery Disease.
Coronary Artery Disease
Q192R polymorphism of the paraoxanase 1 gene and its association with serum lipoprotein variables and carotid artery intima-media thickness in young adults from a biracial community. The Bogalusa Heart Study.
Coronary Artery Disease
Relationship of serum paraoxonase 1 activity and paraoxonase 1 genotype to risk of systemic lupus erythematosus.
Coronary Artery Disease
Serum PON-1 Activity but not Q192R Polymorphism is Related to the Extent of Atherosclerosis.
Coronary Artery Disease
Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease.
Coronary Disease
Daily moderate alcohol consumption increases serum paraoxonase activity; a diet-controlled, randomised intervention study in middle-aged men.
Coronary Disease
Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies.
Coronary Disease
Human serum paraoxonase gene polymorphisms, Q192R and L55M, are not associated with the risk of cerebral infarction in Chinese Han population.
Coronary Disease
Human serum paraoxonase.
Coronary Disease
Plasma homocysteine thiolactone adducts associated with risk of coronary heart disease.
Coronary Disease
Serum paraoxonase activity and phenotype distribution in Turkish subjects with coronary heart disease and its relationship to serum lipids and lipoproteins.
Coronary Disease
The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease.
Coronary Stenosis
PON-1 Activity and Plasma 8-Isoprostane Concentration in Patients with Angiographically Proven Coronary Artery Disease.
Deafness
Paraoxonase 3 gene polymorphisms are associated with occupational noise-induced deafness: A matched case-control study from China.
Deafness
[Association between single nucleotide polymorphisms of PON2 gene and susceptibility to occupational noise-induced deafness among Chinese Han population exposed to high noise levels].
Dementia
Decreased arylesterase activity of paraoxonase-1 (PON-1) might be a common denominator of neuroinflammatory and neurodegenerative diseases.
Dementia
Paraoxonase 1 192/55 gene polymorphisms in Alzheimer's disease.
Dementia
Serum paraoxonase and arylesterase activities of paraoxonase-1 (PON-1), mild cognitive impairment, and 2-year conversion to dementia: A pilot study.
Dementia, Vascular
Codon 311 (Cys --> Ser) polymorphism of paraoxonase-2 gene is associated with apolipoprotein E4 allele in both Alzheimer's and vascular dementias.
Dementia, Vascular
Decreased arylesterase activity of paraoxonase-1 (PON-1) might be a common denominator of neuroinflammatory and neurodegenerative diseases.
Dementia, Vascular
Paraoxonase 1 192/55 gene polymorphisms in Alzheimer's disease.
Dementia, Vascular
PON-1 and ferroxidase activities in older patients with mild cognitive impairment, late onset Alzheimer's disease or vascular dementia.
Dementia, Vascular
Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia.
Dementia, Vascular
Serum paraoxonase and arylesterase activities of paraoxonase-1 (PON-1), mild cognitive impairment, and 2-year conversion to dementia: A pilot study.
Diabetes Complications
Association between PON 1 polymorphisms, PON activity and diabetes complications.
Diabetes Complications
Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus.
Diabetes Complications
The paraoxonase-2-310 polymorphism is associated with the presence of microvascular complications in diabetes mellitus.
Diabetes Mellitus
A case control study on HDL associated PON1 enzyme level in Northern Indian type 2 diabetes mellitus patients.
Diabetes Mellitus
A case-control study: The association of serum paraoxonase 1 activity and concentration with the development of type 2 diabetes mellitus.
Diabetes Mellitus
Antioxidant potential, paraoxonase 1, ceruloplasmin activity and C-reactive protein concentration in diabetic retinopathy.
Diabetes Mellitus
Association between paraoxonase activity and lipid levels in patients with premature coronary artery disease.
Diabetes Mellitus
Association of polymorphism of ser311cys paraoxonase-2 gene with type 2 diabetes mellitus in iran.
Diabetes Mellitus
Association of Serum Paraoxonase 1 Activities, Polymorphisms and Oxidative Stress in Breast Cancer Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus
Effect of Lipoic Acid on Serum Paraoxonase-1 and Paraoxonase-3 Protein Levels and Activities in Diabetic Rats.
Diabetes Mellitus
Effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus.
Diabetes Mellitus
High prevalence of low serum paraoxonase-1 in subjects with coronary artery disease.
Diabetes Mellitus
Human serum paraoxonase gene polymorphisms, Q192R and L55M, are not associated with the risk of cerebral infarction in Chinese Han population.
Diabetes Mellitus
Implications of serum paraoxonase activity in obesity, diabetes mellitus, and dyslipidemia.
Diabetes Mellitus
Increased LCAT activity and hyperglycaemia decrease the antioxidative functionality of HDL.
Diabetes Mellitus
Inverse correlation of serum paraoxonase and homocysteine thiolactonase activities and antioxidant capacity of high-density lipoprotein with the severity of cardiovascular disease in persons with type 2 diabetes mellitus.
Diabetes Mellitus
Investigation of the relationship between atherosclerosis and paraoxonase or homocysteine thiolactonase activity in patients with type 2 diabetes mellitus using a commercially available assay.
Diabetes Mellitus
Lack of association between serum paraoxonase 1 activities and increased oxidized low-density lipoprotein levels in impaired glucose tolerance and newly diagnosed diabetes mellitus.
Diabetes Mellitus
Liver paraoxonase 3 expression and the effect of liraglutide treatment in a rat model of diabetes.
Diabetes Mellitus
Paraoxonase 1: a better atherosclerotic risk predictor than HDL in type 2 diabetes mellitus.
Diabetes Mellitus
Paraoxonase 55 and 192 polymorphism and its relationship to serum paraoxonase activity and serum lipids in Turkish patients with non-insulin dependent diabetes mellitus.
Diabetes Mellitus
Paraoxonase and arylesterase activities in the serum of two hyperlipoproteinaemic patients after repeated extracorporal lipid precipitation.
Diabetes Mellitus
Paraoxonase-1 activity is positively related to phospholipid transfer protein activity in type 2 diabetes mellitus: Role of large HDL particles.
Diabetes Mellitus
Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus.
Diabetes Mellitus
Serum paraoxonase activity and genotype distribution in Japanese patients with diabetes mellitus.
Diabetes Mellitus
Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus.
Diabetes Mellitus
Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins.
Diabetes Mellitus
[Study of SOD and PON-1 expression in type 2 diabetes mellitus nephropathy and its clinical significance].
Diabetes Mellitus
[The effects of paraoxonase-1 and oxidized low density lipoprotein on nephropathy in type-2 diabetes mellitus]
Diabetes Mellitus, Type 1
Antioxidant potential, paraoxonase 1, ceruloplasmin activity and C-reactive protein concentration in diabetic retinopathy.
Diabetes Mellitus, Type 1
Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 1
Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls.
Diabetes Mellitus, Type 2
A case control study on HDL associated PON1 enzyme level in Northern Indian type 2 diabetes mellitus patients.
Diabetes Mellitus, Type 2
A case-control study: The association of serum paraoxonase 1 activity and concentration with the development of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
A randomised controlled trial of increasing fruit and vegetable intake and how this influences the carotenoid concentration and activities of PON-1 and LCAT in HDL from subjects with type 2 diabetes.
Diabetes Mellitus, Type 2
Are PON1 Q/R 192 and M/L 55 polymorphisms risk factors for diabetes complications in Turkish population?
Diabetes Mellitus, Type 2
Association of polymorphism of ser311cys paraoxonase-2 gene with type 2 diabetes mellitus in iran.
Diabetes Mellitus, Type 2
Association of Serum Paraoxonase 1 Activities, Polymorphisms and Oxidative Stress in Breast Cancer Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human serum paraoxonase in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates?
Diabetes Mellitus, Type 2
Incident type 2 diabetes is associated with HDL, but not with its anti-oxidant constituent - paraoxonase-1: The prospective cohort PREVEND study.
Diabetes Mellitus, Type 2
Increased LCAT activity and hyperglycaemia decrease the antioxidative functionality of HDL.
Diabetes Mellitus, Type 2
Inverse correlation of serum paraoxonase and homocysteine thiolactonase activities and antioxidant capacity of high-density lipoprotein with the severity of cardiovascular disease in persons with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Investigation of the relationship between atherosclerosis and paraoxonase or homocysteine thiolactonase activity in patients with type 2 diabetes mellitus using a commercially available assay.
Diabetes Mellitus, Type 2
Paraoxonase 1: a better atherosclerotic risk predictor than HDL in type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Paraoxonase-1 activity is positively related to phospholipid transfer protein activity in type 2 diabetes mellitus: Role of large HDL particles.
Diabetes Mellitus, Type 2
Paraoxonase-2 gene (PON2) G148 variant associated with elevated fasting plasma glucose in noninsulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 2
Paraoxonase-2 variants potentially influence insulin resistance, beta-cell function, and their interrelationships with alanine aminotransferase in type 2 diabetes.
Diabetes Mellitus, Type 2
Relationships between polymorphisms of the human serum paraoxonase gene and insulin sensitivity in Japanese patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Serum paraoxonase activity and genotype distribution in Japanese patients with diabetes mellitus.
Diabetes Mellitus, Type 2
Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 2
The effect of ginger (Zingiber officinale) on glycemic markers in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
The effect of meals rich in thermally stressed olive and safflower oils on postprandial serum paraoxonase activity in patients with diabetes.
Diabetes Mellitus, Type 2
The effect of Omega-3 fatty acids on serum paraoxonase activity, vitamins A, E, and C in type 2 diabetic patients.
Diabetes Mellitus, Type 2
[Study of SOD and PON-1 expression in type 2 diabetes mellitus nephropathy and its clinical significance].
Diabetes Mellitus, Type 2
[The effects of paraoxonase-1 and oxidized low density lipoprotein on nephropathy in type-2 diabetes mellitus]
Diabetes, Gestational
Decreased paraoxonase and arylesterase activities in the pathogenesis of future atherosclerotic heart disease in women with gestational diabetes mellitus.
Diabetic Retinopathy
Antioxidant potential, paraoxonase 1, ceruloplasmin activity and C-reactive protein concentration in diabetic retinopathy.
Drug Resistant Epilepsy
An evaluation of serum paraoxonase together with arylesterase activities and oxidative stress in children with intractable epilepsy: a cross-sectional study.
Dyslipidemias
Association of serum paraoxonase enzyme activity and oxidative stress markers with dyslipidemia in obese adolescents.
Dyslipidemias
Curcumin combined with metformin decreases glycemia and dyslipidemia, and increases paraoxonase activity in diabetic rats.
Dyslipidemias
Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates?
Dyslipidemias
Implications of serum paraoxonase activity in obesity, diabetes mellitus, and dyslipidemia.
Dyslipidemias
Serum lipid profile paraoxonase and arylesterase activities in psoriasis.
Dyslipidemias
THE EFFECT OF ATORVASTATINUM IN THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS.
Dyslipidemias
Visfatin, PON-1 Levels in Iraqi Hyperthyroidism Patient's with Dyslipidemia.
Endometrial Neoplasms
Assessment of serum paraoxonase and arylesterase activity in patients with endometrial cancer.
Endometrial Neoplasms
Serum paraoxonase 1 activity and protein N-homocysteinylation in primary human endometrial cancer.
Endometriosis
Serum paraoxonase-1 activity in women with endometriosis and its relationship with the stage of the disease.
Endometriosis
Serum tumor necrosis factor-?, interleukin-6, monocyte chemotactic protein-1 and paraoxonase-1 profiles in women with endometriosis, PCOS, or unexplained infertility.
Endometriosis
There is no relationship between Paraoxonase serum level activity in women with endometriosis and the stage of the disease: an observational study.
Endotoxemia
Serial measurements of Paraoxonase-1 (PON-1) activity in horses with experimentally induced endotoxemia.
Esophageal Neoplasms
Paraoxonase 3 is involved in the multi-drug resistance of esophageal cancer.
Exfoliation Syndrome
Evaluation of oxidative stress and paraoxonase phenotypes in pseudoexfoliation syndrome and pseudoexfoliation glaucoma.
Fatty Liver
A new marker for lipid peroxidation: Serum paraoxonase activity in non-alcoholic steatohepatitis.
Fatty Liver
Serum paraoxonase activity and oxidative stress and their relationship with obesity-related metabolic syndrome and non-alcoholic fatty liver disease in obese children and adolescents.
Fatty Liver
Serum Paraoxonase as an Indicator for Fatty Liver in Sheep.
Fibromyalgia
Paraoxonase and arylesterase activities in fibromyalgia.
Glaucoma
Evaluation of oxidative stress and paraoxonase phenotypes in pseudoexfoliation syndrome and pseudoexfoliation glaucoma.
Glaucoma
[DNA diagnosis in the age of individual made-to-order medications]
Glioma
Paraoxonase 192 gene polymorphism and serum paraoxonase activity in high grade gliomas and meningiomas.
Glucose Intolerance
Lack of association between serum paraoxonase 1 activities and increased oxidized low-density lipoprotein levels in impaired glucose tolerance and newly diagnosed diabetes mellitus.
Glucose Metabolism Disorders
Serum paraoxonase and cholinesterase activities in individuals with lipid and glucose metabolism disorders.
Head and Neck Neoplasms
Do CO2 and oxidative stress induce cancer?: a brief study about the evaluation of PON 1, CAT, CA and XO enzyme levels on head and neck cancer patients.
Hearing Loss, Sensorineural
Prognostic value of serum anti-heat-shock protein 70 and paraoxonase levels in idiopathic sudden sensorineural hearing loss.
Heart Diseases
Decreased paraoxonase and arylesterase activities in the pathogenesis of future atherosclerotic heart disease in women with gestational diabetes mellitus.
Heart Diseases
Decreased serum paraoxonase 1 (PON1) activity: an additional risk factor for atherosclerotic heart disease in patients with PCOS?
Heart Diseases
New paraoxonase 1 polymorphism I102V and the risk of prostate cancer in Finnish men.
Heart Failure
[Congestive heart failure and paraoxonase]
Hepatitis B
Serum paraoxonase and arylesterase activities in various forms of hepatitis B virus infection.
Hepatitis, Chronic
Serum arylesterase and paraoxonase activity in patients with chronic hepatitis.
Hepatitis, Chronic
Serum paraoxonase and arylesterase activities for the evaluation of patients with chronic hepatitis.
Homocystinuria
Altered expression of apoA-I, apoA-IV and PON-1 activity in CBS deficient homocystinuria in the presence and absence of treatment: Possible implications for cardiovascular outcomes.
Hydatidiform Mole
No association between serum paraoxonase, arylesterase activities, and hydatidiform mole.
Hypercholesterolemia
Association between moderately oxidized low-density lipoprotein and high-density lipoprotein particle subclass distribution in hemodialyzed and post-renal transplant patients.
Hyperemesis Gravidarum
Paraoxonase-1 activity in patients with hyperemesis gravidarum.
Hyperglycemia
The anti-inflammatory function of HDL is impaired in type 2 diabetes: role of hyperglycemia, paraoxonase-1 and low grade inflammation.
Hyperlipidemias
Association between paraoxonase activity and lipid levels in patients with premature coronary artery disease.
Hyperlipidemias
Preanalytical variables affecting the measurement of serum paraoxonase-1 activity in horses.
Hyperlipidemias
The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia.
Hyperlipidemias
The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease.
Hyperlipidemias
The effect of red grape seed extract on serum paraoxonase activity in patients with mild to moderate hyperlipidemia.
Hyperlipidemias
The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia.
Hyperlipoproteinemia Type II
Visfatin, PON-1 Levels in Iraqi Hyperthyroidism Patient's with Dyslipidemia.
Hyperlipoproteinemias
The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease.
Hyperlipoproteinemias
The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia.
Hyperoxaluria
Phytotherapy in a rat model of hyperoxaluria: the antioxidant effects of quercetin involve serum paraoxonase 1 activation.
Hyperpigmentation
Activated neuro-oxidative and neuro-nitrosative pathways at the end of term are associated with inflammation and physio-somatic and depression symptoms, while predicting outcome characteristics in mother and baby.
Hypertension
Association between paraoxonase activity and lipid levels in patients with premature coronary artery disease.
Hypertension
Paraoxonase1 deficiency in mice is associated with hypotension and increased levels of 5,6-epoxyeicosatrienoic acid.
Hypertension
The inverse association of HDL-cholesterol with future risk of hypertension is not modified by its antioxidant constituent, paraoxonase-1: The PREVEND prospective cohort study.
Hyperthyroidism
Association of serum paraoxonase activity with insulin sensitivity and oxidative stress in hyperthyroid and TSH-suppressed nodular goitre patients.
Hyperthyroidism
Serum paraoxonase activity before and after treatment of thyrotoxicosis.
Hyperthyroidism
Subclinical Hyperthyroidism: Status of the Cholesterol Transfers to HDL and Other Parameters Related to Lipoprotein Metabolism in Patients Submitted to Thyroidectomy for Thyroid Cancer.
Hyperthyroidism
Visfatin, PON-1 Levels in Iraqi Hyperthyroidism Patient's with Dyslipidemia.
Hypertriglyceridemia
Association between moderately oxidized low-density lipoprotein and high-density lipoprotein particle subclass distribution in hemodialyzed and post-renal transplant patients.
Hypertriglyceridemia
Interrelationships of serum paraoxonase, serum lipids and apolipoproteins in normal pregnancy. A longitudinal study.
Hypothyroidism
Effect of levothyroxine replacement therapy on paraoxonase-1 and carotid intima-media thickness in subclinical hypothyroidism.
Hypothyroidism
High-dose taurine supplementation increases serum paraoxonase and arylesterase activities in experimental hypothyroidism.
Hypothyroidism
Levothyroxine improves Paraoxonase (PON-1) serum levels in patients with primary hypothyroidism: Case-control study.
Hypothyroidism
Oxidative stress and serum paraoxonase activity in experimental hypothyroidism: effect of vitamin E supplementation.
Hypothyroidism
Serum lipids, tHcy, hs-CRP, MDA and PON-1 levels in SCH and overt hypothyroidism: effect of treatment.
Infections
Application of mass spectrometry to elucidate the pathophysiology of Encephalitozoon cuniculi infection in rabbits.
Infections
Assessing protection against OP pesticides and nerve agents provided by wild-type HuPON1 purified from Trichoplusia ni larvae or induced via adenoviral infection.
Infections
Decreased serum paraoxonase-1 activity during intestinal nematode (Nippostrongylus brasiliensis) infection in rats.
Infections
Directed Enzyme Evolution and Encapsulation in Peptide Nanospheres of Quorum Quenching Lactonase as an Antibacterial Treatment against Plant Pathogen.
Infections
Expression of Pseudomonas phosphotriesterase activity in the fall armyworm confers resistance to insecticides.
Infections
Gene delivery of paraoxonase-1 inhibits neointimal hyperplasia after arterial balloon-injury in rabbits fed a high-fat diet.
Infections
Hepatoprotective immune response during Trichinella spiralis infection in mice.
Infections
Paraoxonases-2 and -3 Are Important Defense Enzymes against Pseudomonas aeruginosa Virulence Factors due to Their Anti-Oxidative and Anti-Inflammatory Properties.
Infections
Serum ferritin and paraoxonase-1 in canine leishmaniosis.
Infertility
Paraoxonase-1 Activity in Subfertile Men and Relationship to Sperm Parameters.
Infertility
Serum tumor necrosis factor-?, interleukin-6, monocyte chemotactic protein-1 and paraoxonase-1 profiles in women with endometriosis, PCOS, or unexplained infertility.
Infertility, Female
Association between Serum Paraoxonase 1 Activities (PONase/AREase) and L55M Polymorphism in Risk of Female Infertility.
Infertility, Male
[Clinical value of seminal paraoxonase-1 activity evaluation in the diagnosis of male infertility].
Insulin Resistance
Association of serum paraoxonase activity with insulin sensitivity and oxidative stress in hyperthyroid and TSH-suppressed nodular goitre patients.
Insulin Resistance
Body iron stores and glucose intolerance in premenopausal women: role of hyperandrogenism, insulin resistance and genomic variants related to inflammation, oxidative stress and iron metabolism.
Insulin Resistance
Effect of insulin resistance on serum paraoxonase activity in a nondiabetic population.
Insulin Resistance
Lower Serum Paraoxonase-1 Activity Is Related to Linoleic and Docosahexanoic Fatty Acids in Patients with Type 2 Diabetes.
Insulin Resistance
Paraoxonase-2 variants potentially influence insulin resistance, beta-cell function, and their interrelationships with alanine aminotransferase in type 2 diabetes.
Insulin Resistance
Relationships between polymorphisms of the human serum paraoxonase gene and insulin sensitivity in Japanese patients with type 2 diabetes.
Iron Deficiencies
Paraoxonase activity in athletes with depleted iron stores and iron-deficient erythropoiesis.
Ischemic Stroke
R-carrying genotypes of serum paraoxonase (PON1) 192 polymorphism and higher activity ratio are related to susceptibility against ischemic stroke.
Ischemic Stroke
Relation of Paraoxonase1, Arylesterase and Lipid Profile in Ischemic Stroke Patients.
Ischemic Stroke
The salt stimulation property of serum paraoxonase (PON1) could be a valuable factor in evaluating the enzyme status in ischemic stroke: the role of activity-determined PON1 192Q/R phenotypes.
Keratosis, Actinic
Differential immunohistochemical expression of paraoxonase-2 in actinic keratosis and squamous cell carcinoma.
Ketosis
Predictive Value of Plasma Parameters in the Risk of Postpartum Ketosis in Dairy Cows.
Kidney Diseases
Decrease of serum paraoxonase activity in chronic renal failure.
Kidney Failure, Chronic
Activity of paraoxonase 1 (PON1) on HDL2 and HDL3 subclasses in renal disease.
Kidney Failure, Chronic
Decrease of serum paraoxonase activity in chronic renal failure.
Kidney Failure, Chronic
Paraoxonase activity and antibodies to oxidized-LDL in chronic renal failure patients on renal replacement therapy.
Kidney Failure, Chronic
Paraoxonase-1 and ischemia-modified albumin in patients with end-stage renal disease.
Kidney Failure, Chronic
Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance.
Kidney Failure, Chronic
Serum paraoxonase 1 (PON1) lactonase activity is lower in end-stage renal disease patients than in healthy control subjects and increases after hemodialysis.
Kidney Failure, Chronic
Serum paraoxonase activity and protein thiols in chronic renal failure patients.
Kidney Failure, Chronic
Serum paraoxonase activity, high-sensitivity C-reactive protein, and lipoprotein disturbances in end-stage renal disease patients on long-term hemodialysis.
Kidney Failure, Chronic
Serum paraoxonase and platelet-activating factor acetylhydrolase in chronic renal failure.
Kidney Failure, Chronic
The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia.
Leukemia
The anti-apoptotic PON2 protein is Wnt/?-catenin-regulated and correlates with radiotherapy resistance in OSCC patients.
Leukemia, Myeloid, Acute
The activities of serum paraoxonase and arylesterase and lipid profile in acute myeloid leukemia: preliminary results.
Liver Cirrhosis
Serum fucosylated paraoxonase 1 as a potential glycobiomarker for clinical diagnosis of early hepatocellular carcinoma using ELISA Index.
Liver Cirrhosis
Serum paraoxonase 1 heteroplasmon, a fucosylated, and sialylated glycoprotein in distinguishing early hepatocellular carcinoma from liver cirrhosis patients.
Liver Diseases
Baseline and salt-stimulated paraoxonase and arylesterase activities in patients with chronic liver disease: relation to disease severity.
Liver Diseases
Baseline and Salt-stimulated Paraoxonase and Arylesterase Activities in Patients with Chronic Liver Disease: Relation with Disease Severity.
Liver Diseases
Serum paraoxonase 1 activity is paradoxically maintained in nonalcoholic fatty liver disease despite low HDL cholesterol.
Liver Diseases
Serum paraoxonase activity and oxidative stress and their relationship with obesity-related metabolic syndrome and non-alcoholic fatty liver disease in obese children and adolescents.
Liver Diseases
Serum paraoxonase and arylesterase activities in Iranian patients with nonalcoholic fatty liver disease.
Liver Diseases
Serum paraoxonase levels in patients with acute liver disease.
Liver Diseases, Alcoholic
Serum paraoxonase in alcohol abusers associated with alcoholic liver disease.
Lung Diseases
Serum paraoxonase and arylesterase activities in patients with pulmonary tuberculosis.
Lung Neoplasms
Integrated Glycoproteomics Demonstrates Fucosylated Serum Paraoxonase 1 Alterations in Small Cell Lung Cancer.
Lung Neoplasms
Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population.
Lupus Erythematosus, Systemic
Association analysis of PON2 genetic variants with serum paraoxonase activity and systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Relationship of serum paraoxonase 1 activity and paraoxonase 1 genotype to risk of systemic lupus erythematosus.
Macular Degeneration
Decreased serum paraoxonase 1 activity and increased serum homocysteine and malondialdehyde levels in age-related macular degeneration.
Macular Degeneration
Serum paraoxonase 1 activity and lipid peroxidation levels in patients with age-related macular degeneration.
Macular Degeneration
Serum Paraoxonase activity in relation to lipid profile in Age-related Macular Degeneration patients.
Macular Degeneration
SERUM PARAOXONASE PHENOTYPE DISTRIBUTION IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION AND ITS RELATIONSHIP TO HOMOCYSTEINE AND OXIDIZED LOW-DENSITY LIPOPROTEIN.
Melanoma
Paraoxonase-2 Silencing Enhances Sensitivity of A375 Melanoma Cells to Treatment with Cisplatin.
Meningioma
Paraoxonase 192 gene polymorphism and serum paraoxonase activity in high grade gliomas and meningiomas.
Metabolic Syndrome
Low levels of serum paraoxonase activities are characteristic of metabolic syndrome and may influence the metabolic-syndrome-related risk of coronary artery disease.
Metabolic Syndrome
Lower serum paraoxonase-1 activity is related to higher serum amyloid a levels in metabolic syndrome.
Metabolic Syndrome
Non-diabetic metabolic syndrome and obesity do not affect serum paraoxonase and arylesterase activities but do affect oxidative stress and inflammation.
Metabolic Syndrome
Relationship of serum resistin level to traits of metabolic syndrome and serum paraoxonase 1 activity in a population with a broad range of body mass index.
Metabolic Syndrome
Serum paraoxonase 1 activity in women with metabolic syndrome.
Metabolic Syndrome
Serum paraoxonase activity and oxidative stress and their relationship with obesity-related metabolic syndrome and non-alcoholic fatty liver disease in obese children and adolescents.
Metabolic Syndrome
Serum paraoxonase and arylesterase activities in metabolic syndrome in Zahedan, southeast Iran.
Metabolic Syndrome
Serum paraoxonase-1 activities and oxidative status in patients with plaque-type psoriasis with/without metabolic syndrome.
Metabolic Syndrome
The positive relationship of serum paraoxonase-1 activity with apolipoprotein E is abrogated in metabolic syndrome.
Metabolic Syndrome
The role of abnormalities of lipoproteins and HDL functionality in small fibre dysfunction in people with severe obesity.
Microvascular Angina
Paraoxonase and arylesterase activities in patients with cardiac syndrome X, and their relationship with oxidative stress markers.
Microvascular Angina
Serum paraoxonase 1 activity and oxidative markers of LDL in patients with cardiac syndrome X.
Migraine Disorders
Paraoxonase 1 gene polymorphisms, paraoxonase/arylesterase activities and oxidized low-density lipoprotein levels in patients with migraine.
Multiple Sclerosis
Association between serum paraoxonase 1 activity and its polymorphisms with multiple sclerosis: a systematic review.
Multiple Sclerosis
Decreased arylesterase activity of paraoxonase-1 (PON-1) might be a common denominator of neuroinflammatory and neurodegenerative diseases.
Multiple Sclerosis
Serum paraoxonase and arylesterase activity and oxidative status in patients with multiple sclerosis.
Multiple Sclerosis, Relapsing-Remitting
Serum paraoxonase and arylesterase activity and oxidative status in patients with multiple sclerosis.
Myocardial Infarction
Association between paraoxonase-1 and paraoxonase-2 polymorphisms and the risk of acute myocardial infarction.
Myocardial Infarction
Clinical and Genetic Association of Serum Paraoxonase and Arylesterase Activities With Cardiovascular Risk.
Myocardial Infarction
Relationship between Paraoxonase-1 and Arylesterase Enzyme Activities and SYNTAX I and II Scores in Patients with ST-Elevation Myocardial Infarction.
Myocardial Infarction
Serum Paraoxonase (PON1) Activity in North-West Indian Punjabi's with Acute Myocardial Infarction.
Myocardial Infarction
Serum paraoxonase after myocardial infarction.
Myocardial Infarction
Smoking is associated with reduced serum paraoxonase, antioxidants and increased oxidative stress in normolipidaemic acute myocardial infarct patients.
Myocardial Infarction
The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study.
Myocardial Infarction
[Association between paraoxonase-1 and paraoxonase-2 polymorphisms and the risk of acute myocardial infarction]
Myocardial Ischemia
Paraoxonase variants relate to 10-year risk in coronary artery disease: impact of a high-density lipoprotein-bound antioxidant in secondary prevention.
Nasal Polyps
Serum paraoxonase, arylesterase activity, and oxidative status in patients with nasal polyp.
Neonatal Sepsis
Paraoxonase (PON)-1 activity in septic neonates: One more arrow in the quiver of biomarkers of neonatal sepsis?
Neonatal Sepsis
Total Antioxidan Level, Total Oxidan Level and Serum Paraoxonase-1 Levels in Neonatal Sepsis.
Neoplasm Metastasis
Paraoxonase 3 promotes cell proliferation and metastasis by PI3K/Akt in oral squamous cell carcinoma.
Neoplasms
Bladder Cancer Chemosensitivity is Affected by Paraoxonase-2 Expression.
Neoplasms
Is there a relation between genetic susceptibility with cancer? A study about paraoxanase (PON1) enzyme activity in breast cancer cases.
Neoplasms
Mechanistic insights and perspectives involved in neuroprotective action of quercetin.
Neoplasms
Oxidative stress parameters and inflammatory and immune mediators as markers of the severity of sepsis.
Neoplasms
Paraoxonase 3 promotes cell proliferation and metastasis by PI3K/Akt in oral squamous cell carcinoma.
Neoplasms
Paraoxonase-2 (PON2) protects oral squamous cell cancer cells against irradiation-induced apoptosis.
Neoplasms
Physical activity is associated with a large number of cardiovascular-specific proteins: Cross-sectional analyses in two independent cohorts.
Neoplasms
Stress-Related Regulation Is Abnormal in the Psoriatic Uninvolved Skin.
Neoplasms
The anti-apoptotic PON2 protein is Wnt/?-catenin-regulated and correlates with radiotherapy resistance in OSCC patients.
Neoplasms
The anti-inflammatory function of HDL is impaired in type 2 diabetes: role of hyperglycemia, paraoxonase-1 and low grade inflammation.
Neoplasms, Squamous Cell
Paraoxonase-2 (PON2) protects oral squamous cell cancer cells against irradiation-induced apoptosis.
Neoplasms, Squamous Cell
The anti-apoptotic PON2 protein is Wnt/?-catenin-regulated and correlates with radiotherapy resistance in OSCC patients.
Nephrotic Syndrome
Serum paraoxonase activity and oxidative stress in patients with adult nephrotic syndrome.
Neuroblastoma
Degradation of organophosphorus neurotoxicity in SY5Y neuroblastoma cells by organophosphorus hydrolase (OPH).
Non-alcoholic Fatty Liver Disease
Paraoxonase 1 and Non-Alcoholic Fatty Liver Disease: A Meta-Analysis.
Non-alcoholic Fatty Liver Disease
Serum paraoxonase 1 activity is paradoxically maintained in nonalcoholic fatty liver disease despite low HDL cholesterol.
Non-alcoholic Fatty Liver Disease
Serum paraoxonase activity and oxidative stress and their relationship with obesity-related metabolic syndrome and non-alcoholic fatty liver disease in obese children and adolescents.
Non-alcoholic Fatty Liver Disease
Serum paraoxonase and arylesterase activities in Iranian patients with nonalcoholic fatty liver disease.
Obesity
Association between paraoxonase activity and lipid levels in patients with premature coronary artery disease.
Obesity
Changes in lipid profile parameters and PON1 status associated with L55M PON1 polymorphism, overweight and exposure to tobacco smoke.
Obesity
Changes on the physiological lactonase activity of serum paraoxonase 1 by a diet intervention for weight loss in healthy overweight and obese women.
Obesity
Decreased obesity and atherosclerosis in human paraoxonase 3 transgenic mice.
Obesity
Gender related differences in paraoxonase 1 response to high-fat diet-induced oxidative stress.
Obesity
Implications of serum paraoxonase activity in obesity, diabetes mellitus, and dyslipidemia.
Obesity
Non-diabetic metabolic syndrome and obesity do not affect serum paraoxonase and arylesterase activities but do affect oxidative stress and inflammation.
Osteoarthritis
Expression of proteins in serum, synovial fluid, synovial membrane, and articular cartilage samples obtained from dogs with stifle joint osteoarthritis secondary to cranial cruciate ligament disease and dogs without stifle joint arthritis.
Osteoarthritis, Knee
Assessment of paraoxonase activities in patients with knee osteoarthritis.
Osteomyelitis
The activity of paraoxonase and arylesterase in patients with osteomyelitis.
Osteonecrosis
Association of a polymorphism in PON-1 gene with steroid-induced osteonecrosis of femoral head in Chinese Han population.
Otitis Media
Serum paraoxonase and arylesterase activities in patients with chronic otitis media.
Overweight
Changes in lipid profile parameters and PON1 status associated with L55M PON1 polymorphism, overweight and exposure to tobacco smoke.
Overweight
Changes on the physiological lactonase activity of serum paraoxonase 1 by a diet intervention for weight loss in healthy overweight and obese women.
Overweight
Polycystic ovary syndrome and endothelial dysfunction: A potential role for soluble lectin-like oxidized low density lipoprotein receptor-1.
Pancreatic Neoplasms
Serum paraoxonase levels in pancreatic cancer.
Pancreatitis
Serum paraoxonase (a high-density lipoprotein-associated lipophilic antioxidant) activity and lipid profile in experimental acute pancreatitis.
Pancreatitis
Serum paraoxonase (a high-density lipoprotein-associated lipophilic antioxidant) activity in clinical follow-up of patients with acute pancreatitis, with particular emphasis on oxidative stress parameters and lipid profile: a prospective pilot trial.
Pancreatitis
Serum paraoxonase 1 (PON1) activity in acute pancreatitis of dogs.
Pancreatitis
Serum paraoxonase undergoes inhibition and proteolysis during experimental acute pancreatitis.
Pancreatitis, Chronic
Decreased Serum Paraoxonase Activity in Patients With Chronic Pancreatitis.
Parkinson Disease
Paraoxonase 1 polymorphisms L55M and Q192R were not risk factors for Parkinson's disease: a HuGE review and meta-analysis.
Parkinson Disease
Paraoxonase and arylesterase activity and total oxidative/anti-oxidative status in patients with idiopathic Parkinson's disease.
Peripheral Nervous System Diseases
Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins.
Polycystic Kidney Diseases
A mouse kidney- and liver-expressed cDNA having homology with a prokaryotic parathion hydrolase (phosphotriesterase)-encoding gene: abnormal expression in injured and polycystic kidneys.
Polycystic Ovary Syndrome
Benefits of omega-3 Fatty acids supplementation on serum paraoxonase 1 activity and lipids ratios in polycystic ovary syndrome.
Polycystic Ovary Syndrome
Serum paraoxonase 1 activity and oxidant/antioxidant status in Saudi women with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Serum paraoxonase 1 activity, asymmetric dimethylarginine levels, and brachial artery flow-mediated dilatation in women with polycystic ovary syndrome.
Polycystic Ovary Syndrome
The PON1-108C/T polymorphism, and not the polycystic ovary syndrome, is an important determinant of reduced serum paraoxonase activity in premenopausal women.
Pre-Eclampsia
Levels of oxidized LDL, estrogens, and progesterone in placenta tissues and serum paraoxonase activity in preeclampsia.
Pre-Eclampsia
Oxidizability of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in preeclampsia.
Pre-Eclampsia
Serum levels of lipids, lipoproteins and paraoxonase activity in pre-eclampsia.
Prostatic Neoplasms
Enhanced HDL-cholesterol-associated anti-oxidant PON-1 activity in prostate cancer patients.
Proteinuria
Serum paraoxonase activity and oxidative stress in patients with adult nephrotic syndrome.
Psoriasis
Association Between Oxidation-Modified Lipoproteins and Coronary Plaque in Psoriasis.
Psoriasis
HDL associated paraoxonase-1 activity correlates with systemic inflammation, disease activity and cardiovascular risk factors in psoriatic disease.
Psoriasis
Serum lipid profile paraoxonase and arylesterase activities in psoriasis.
Psoriasis
Serum paraoxonase-1 activities and oxidative status in patients with plaque-type psoriasis with/without metabolic syndrome.
Pulmonary Disease, Chronic Obstructive
Evaluation of serum paraoxonase and arylesterase activities in subjects with asthma and chronic obstructive lung disease.
Renal Insufficiency
Acrolein inactivates paraoxonase 1: changes in free acrolein levels after hemodialysis correlate with increases in paraoxonase 1 activity in chronic renal failure patients.
Renal Insufficiency, Chronic
Circulating Lactonase Activity but Not Protein Level of PON-1 Predicts Adverse Outcomes in Subjects with Chronic Kidney Disease.
Renal Insufficiency, Chronic
Comparison of serum paraoxonase and arylesterase activities between iron deficiency anemia patients and chronic kidney disease patients with anemia.
Renal Insufficiency, Chronic
Diminished antioxidant activity of high-density lipoprotein-associated proteins in chronic kidney disease.
Renal Insufficiency, Chronic
Serum Paraoxonase Levels are Correlated with Impaired Aortic Functions in Patients with Chronic Kidney Disease.
Rosacea
Assessment of decreased serum paraoxonase activity in patients with rosacea in terms of methodology.
Rosacea
Decreased serum paraoxonase and arylesterase activities in patients with rosacea.
Rosacea
Response to 'Letter to the editor' by Agilli et al. entitled 'Assessment of decreased serum paraoxonase activity in patients with rosacea in terms of methodology'
Sepsis
A fluorogenic substrate for detection of organophosphatase activity.
Sepsis
Decreased paraoxonase activity in critically ill patients with sepsis.
Sepsis
Identification of Protein Carbonyls (PCOs) in Canine Serum by Western Blot Technique and Preliminary Evaluation of PCO Concentration in Dogs With Systemic Inflammation.
Sepsis
Oxidative stress parameters and inflammatory and immune mediators as markers of the severity of sepsis.
Sepsis
Paraoxonase (PON)-1 activity in septic neonates: One more arrow in the quiver of biomarkers of neonatal sepsis?
Sepsis
Prognostic value of serum paraoxonase and arylesterase activity in patients with sepsis.
Sepsis
The diagnostic and prognostic value of paraoxonase-1 and butyrylcholinesterase activities compared with acute-phase proteins in septic dogs and stratified by the acute patient physiologic and laboratory evaluation score.
Skin Neoplasms
Paraoxonase-2: A potential biomarker for skin cancer aggressiveness.
Sleep Apnea, Obstructive
Serum paraoxonase, arylesterase activity and oxidative status in patients with obstructive sleep apnea syndrome (OSAS).
Sleep Initiation and Maintenance Disorders
Serum paraoxonase, arylesterase activities and oxidative status in patients with insomnia.
Small Cell Lung Carcinoma
Integrated Glycoproteomics Demonstrates Fucosylated Serum Paraoxonase 1 Alterations in Small Cell Lung Cancer.
Spondylitis, Ankylosing
Carotid intima-media thickness and paraoxonase activity in patients with ankylosing spondylitis.
Spondylitis, Ankylosing
Evaluation of serum paraoxonase and arylesterase activities in ankylosing spondylitis patients.
Squamous Cell Carcinoma of Head and Neck
Measurement of serum paraoxonase activity and MDA concentrations in patients suffering with oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Oral squamous cell carcinoma and serum paraoxonase 1.
Squamous Cell Carcinoma of Head and Neck
Paraoxonase 3 promotes cell proliferation and metastasis by PI3K/Akt in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Serum paraoxonase activity and oxidative DNA damage in patients with laryngeal squamous cell carcinoma.
ST Elevation Myocardial Infarction
Oxidative Stress and Paraoxonase 1 Activity Predict Contrast-Induced Nephropathy in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
ST Elevation Myocardial Infarction
Relationship between Paraoxonase-1 and Arylesterase Enzyme Activities and SYNTAX I and II Scores in Patients with ST-Elevation Myocardial Infarction.
Stomach Neoplasms
Serum paraoxonase levels in gastric cancer.
Stomach Neoplasms
The clinical and prognostic significance of paraoxonase-2 in gastric cancer patients: immunohistochemical analysis.
Stomatitis, Aphthous
Assessment of the serum paraoxonase activity and oxidant/antioxidant status in patients with recurrent aphthous stomatitis.
Stroke
Anti-(apolipoprotein A-1) IgGs are associated with high levels of oxidized low-density lipoprotein in acute coronary syndrome.
Stroke
Shared genetic risk factors for depression and stroke.
Stroke, Lacunar
Serum paraoxonase and arylesterase activities in patients with lacunar infarction: a case control study.
Thyrotoxicosis
Serum paraoxonase activity before and after treatment of thyrotoxicosis.
Tuberculosis
Overexpression, crystallization and preliminary X-ray crystallographic analysis of the phosphotriesterase from Mycobacterium tuberculosis.
Tuberculosis
Serum paraoxonase and arylesterase activities in patients with pulmonary tuberculosis.
Tuberculosis, Pulmonary
Serum paraoxonase 1 activity and oxidative stress in pediatric patients with pulmonary tuberculosis.
Tuberculosis, Pulmonary
Serum paraoxonase and arylesterase activities in patients with pulmonary tuberculosis.
Uremia
PON-1 carbamylation is enhanced in HDL of uremia patients.
Urinary Bladder Neoplasms
Bladder Cancer Chemosensitivity is Affected by Paraoxonase-2 Expression.
Urinary Bladder Neoplasms
Exploring the role of paraoxonase-2 in bladder cancer: analyses performed on tissue samples, urines and cell cultures.
Vascular Diseases
Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity.
Vascular Diseases
Paraoxonase variants relate to 10-year risk in coronary artery disease: impact of a high-density lipoprotein-bound antioxidant in secondary prevention.
Vascular Diseases
Paraoxonase-1 (PON1) activity as a risk factor for atherosclerosis in chronic renal failure patients.
Vascular Diseases
Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation.
Vascular Diseases
The salt stimulation property of serum paraoxonase (PON1) could be a valuable factor in evaluating the enzyme status in ischemic stroke: the role of activity-determined PON1 192Q/R phenotypes.
Vitamin A Deficiency
Alterations in the lipid metabolism of rat aorta: effects of vitamin a deficiency.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.27 - 9160
2,4-dinitrophenyl diethyl phosphate
0.062 - 950
2,6-difluorophenyl diethyl phosphate
3.7
2-fluoro 4-nitrophenyl diethyl phosphate
pH 8.0
11080
2-fluoro-4-nitrophenyl diethyl phosphate
pH 8.0, genetic variant PON1 G2E6
10.2 - 1477
3,5-dinitrophenyl diethyl phosphate
0.178 - 1610
3-cyanophenyl diethyl phosphate
13.9
3-fluoro 4-nitrophenyl diethyl phosphate
pH 8.0
11680
3-fluoro-4-nitrophenyl diethyl phosphate
pH 8.0, genetic variant PON1 G2E6
0.0011 - 656
3-fluorophenyl diethyl phosphate
0.076 - 840
3-nitrophenyl diethyl phosphate
13
4-acetoxy acetophenone
pH 8.0, genetic variant PON1 G2E6
0.0008 - 848
4-chlorophenyl diethyl phosphate
0.4 - 7495
4-cyanophenyl diethyl phosphate
0.44 - 8080
4-diethyl phosphate acetophenone
0.47 - 12620
4-diethyl phosphate benzaldehyde
5485
4-diethyl phosphate methyl benzoate
pH 8.0, genetic variant PON1 G2E6
4.8 - 10520
4-nitrophenyl diethyl phosphate
166
5-(thiobutyryl)butyrolactone
pH 8.0, recombinant wild-type PON1 genetic variant G2E6
0.02
Benzyl acetate
about, pH 8.0, genetic variant PON1 G2E6
0.104 - 0.202
diethyl-paraoxon
0.1 - 10.7
dimethyl-paraoxon
0.24
ethyl acetate
pH 8.0, genetic variant PON1 G2E6
0.6 - 678
pentafluorophenyl diethyl phosphate
0.41 - 8.5
4-acetylphenyl (2R)-3,3-dimethylbutan-2-yl (R)-methylphosphonate
0.21 - 1.5
4-acetylphenyl (2R)-3,3-dimethylbutan-2-yl (S)-methylphosphonate
0.016 - 2.9
4-acetylphenyl (2S)-3,3-dimethylbutan-2-yl (S)-methylphosphonate
20 - 110
4-acetylphenyl 2-methylpropyl (R)-methylphosphonate
12 - 100
4-acetylphenyl 2-methylpropyl (S)-methylphosphonate
0.81 - 150
4-acetylphenyl cyclohexyl (R)-methylphosphonate
0.14 - 19
4-acetylphenyl cyclohexyl (S)-methylphosphonate
7.3 - 150
4-acetylphenyl ethyl (R)-methylphosphonate
110 - 670
4-acetylphenyl ethyl (S)-methylphosphonate
18 - 250
4-acetylphenyl propan-2-yl (R)-methylphosphonate
7.4 - 370
4-acetylphenyl propan-2-yl (S)-methylphosphonate
4.3 - 5.7
diethyl paraoxon
698
dihydrocoumarin
-
recombinant PON3
0.1
O-isobutyl-S-[2-(diethylamino)ethyl]methylphosphonothioic acid
-
in 50 mM Tris-HCl buffer, 10 mM CaCl2, pH 7.4
additional information
additional information
-
-
0.27
2,4-dinitrophenyl diethyl phosphate
pH 8.0
9160
2,4-dinitrophenyl diethyl phosphate
pH 8.0, genetic variant PON1 G2E6
0.062
2,6-difluorophenyl diethyl phosphate
pH 8.0
950
2,6-difluorophenyl diethyl phosphate
pH 8.0, genetic variant PON1 G2E6
10.2
3,5-dinitrophenyl diethyl phosphate
pH 8.0
1477
3,5-dinitrophenyl diethyl phosphate
pH 8.0, genetic variant PON1 G2E6
0.178
3-cyanophenyl diethyl phosphate
pH 8.0
1610
3-cyanophenyl diethyl phosphate
pH 8.0, genetic variant PON1 G2E6
0.0011
3-fluorophenyl diethyl phosphate
pH 8.0
656
3-fluorophenyl diethyl phosphate
pH 8.0, genetic variant PON1 G2E6
0.076
3-nitrophenyl diethyl phosphate
pH 8.0
840
3-nitrophenyl diethyl phosphate
pH 8.0, genetic variant PON1 G2E6
0.0008
4-chlorophenyl diethyl phosphate
pH 8.0
848
4-chlorophenyl diethyl phosphate
pH 8.0, genetic variant PON1 G2E6
0.4
4-cyanophenyl diethyl phosphate
pH 8.0
7495
4-cyanophenyl diethyl phosphate
pH 8.0, genetic variant PON1 G2E6
0.44
4-diethyl phosphate acetophenone
pH 8.0
8080
4-diethyl phosphate acetophenone
pH 8.0, genetic variant PON1 G2E6
0.47
4-diethyl phosphate benzaldehyde
pH 8.0
12620
4-diethyl phosphate benzaldehyde
pH 8.0, genetic variant PON1 G2E6
4.8
4-nitrophenyl diethyl phosphate
pH 8.0
10520
4-nitrophenyl diethyl phosphate
pH 8.0, genetic variant PON1 G2E6
0.104
diethyl-paraoxon
pH 10.5, 25°C, recombinant PON1 wild-type enzyme
0.202
diethyl-paraoxon
pH 10.5, 25°C, recombinant PON1-hFc fusion enzyme
0.1
dimethyl-paraoxon
pH 8.0, 25°C, recombinant mutant H115W/R192I
0.2
dimethyl-paraoxon
pH 8.0, 25°C, recombinant mutant H115W/R192S
0.9
dimethyl-paraoxon
pH 8.0, 25°C, recombinant wild-type enzyme
3.8
dimethyl-paraoxon
pH 8.0, 25°C, recombinant mutant H115W/R192N
4.2
dimethyl-paraoxon
pH 8.0, 25°C, recombinant mutant H115W/R192W
6
dimethyl-paraoxon
pH 8.0, 25°C, recombinant mutants H115W
7.7
dimethyl-paraoxon
pH 8.0, 25°C, recombinant mutant H115W/R192A
10.7
dimethyl-paraoxon
pH 8.0, 25°C, recombinant mutant H115W/R192K
0.54
paraoxon
pH 8.0, recombinant genetic variant G1C4
0.87
paraoxon
pH 8.0, recombinant genetic variant G2E6
0.89
paraoxon
pH 8.0, temperature not specified in the publication
0.9
paraoxon
wild-type, pH 8.0, 25°C
0.98
paraoxon
pH 8.0, recombinant genetic variant G2D6
1
paraoxon
pH 8.0, mutant enzyme H115Q
1.09
paraoxon
pH 8.0, recombinant wild-type PON1 genetic variant G2E6
1.1
paraoxon
pH 8.0, recombinant genetic variant G3C9
1.16
paraoxon
pH 8.0, recombinant genetic variant G1A5
1.2
paraoxon
pH 8.0, recombinant genetic variant G3H8
3
paraoxon
pH 8.0, wild-type enzyme
3.3
paraoxon
pH 8.3, activity buffer
3.7
paraoxon
pH 8.3, activity buffer with 0.01 mM apolipoprotein apoA-I rHDL
3.8
paraoxon
mutant H115W/R192Q, pH 8.0, 25°C
4.2
paraoxon
pH 8.0, wild-type enzyme
4.7
paraoxon
pH 8.0, mutant enzyme H115Q/H134Q
4.8
paraoxon
recombinant enzyme
5.8
paraoxon
pH 8.3, activity buffer with 0.1% tergitol
6
paraoxon
mutant H115W, pH 8.0, 25°C
10.7
paraoxon
mutant H115W/R192K, pH 8.0, 25°C
12.7
paraoxon
pH 8.0, mutant enzyme H134Q
0.6
pentafluorophenyl diethyl phosphate
pH 8.0
678
pentafluorophenyl diethyl phosphate
about, pH 8.0, genetic variant PON1 G2E6
0.41
4-acetylphenyl (2R)-3,3-dimethylbutan-2-yl (R)-methylphosphonate
-
mutant enzyme H275Y/L303T, in 50 mM CHES (pH 9.0), at 30°C
2
4-acetylphenyl (2R)-3,3-dimethylbutan-2-yl (R)-methylphosphonate
-
mutant enzyme H254G/H257W/L303T, in 50 mM CHES (pH 9.0), at 30°C
2.2
4-acetylphenyl (2R)-3,3-dimethylbutan-2-yl (R)-methylphosphonate
-
mutant enzyme S308G, in 50 mM CHES (pH 9.0), at 30°C
3.4
4-acetylphenyl (2R)-3,3-dimethylbutan-2-yl (R)-methylphosphonate
-
wild type enzyme, in 50 mM CHES (pH 9.0), at 30°C
8.5
4-acetylphenyl (2R)-3,3-dimethylbutan-2-yl (R)-methylphosphonate
-
mutant enzyme G60A, in 50 mM CHES (pH 9.0), at 30°C
0.21
4-acetylphenyl (2R)-3,3-dimethylbutan-2-yl (S)-methylphosphonate
-
mutant enzyme H254G/H257W/L303T, in 50 mM CHES (pH 9.0), at 30°C
0.45
4-acetylphenyl (2R)-3,3-dimethylbutan-2-yl (S)-methylphosphonate
-
wild type enzyme, in 50 mM CHES (pH 9.0), at 30°C
0.62
4-acetylphenyl (2R)-3,3-dimethylbutan-2-yl (S)-methylphosphonate
-
mutant enzyme S308G, in 50 mM CHES (pH 9.0), at 30°C
1.5
4-acetylphenyl (2R)-3,3-dimethylbutan-2-yl (S)-methylphosphonate
-
mutant enzyme G60A, in 50 mM CHES (pH 9.0), at 30°C
0.016
4-acetylphenyl (2S)-3,3-dimethylbutan-2-yl (S)-methylphosphonate
-
wild type enzyme, in 50 mM CHES (pH 9.0), at 30°C
0.12
4-acetylphenyl (2S)-3,3-dimethylbutan-2-yl (S)-methylphosphonate
-
mutant enzyme S308G, in 50 mM CHES (pH 9.0), at 30°C
2.1
4-acetylphenyl (2S)-3,3-dimethylbutan-2-yl (S)-methylphosphonate
-
mutant enzyme H275Y/L303T, in 50 mM CHES (pH 9.0), at 30°C
2.9
4-acetylphenyl (2S)-3,3-dimethylbutan-2-yl (S)-methylphosphonate
-
mutant enzyme H254G/H257W/L303T, in 50 mM CHES (pH 9.0), at 30°C
20
4-acetylphenyl 2-methylpropyl (R)-methylphosphonate
-
mutant enzyme H254G/H257W/L303T, in 50 mM CHES (pH 9.0), at 30°C
37
4-acetylphenyl 2-methylpropyl (R)-methylphosphonate
-
mutant enzyme G60A, in 50 mM CHES (pH 9.0), at 30°C
51
4-acetylphenyl 2-methylpropyl (R)-methylphosphonate
-
mutant enzyme H275Y/L303T, in 50 mM CHES (pH 9.0), at 30°C
93
4-acetylphenyl 2-methylpropyl (R)-methylphosphonate
-
wild type enzyme, in 50 mM CHES (pH 9.0), at 30°C
110
4-acetylphenyl 2-methylpropyl (R)-methylphosphonate
-
mutant enzyme S308G, in 50 mM CHES (pH 9.0), at 30°C
12
4-acetylphenyl 2-methylpropyl (S)-methylphosphonate
-
mutant enzyme S308G, in 50 mM CHES (pH 9.0), at 30°C
22
4-acetylphenyl 2-methylpropyl (S)-methylphosphonate
-
wild type enzyme, in 50 mM CHES (pH 9.0), at 30°C
50
4-acetylphenyl 2-methylpropyl (S)-methylphosphonate
-
mutant enzyme H254G/H257W/L303T, in 50 mM CHES (pH 9.0), at 30°C
100
4-acetylphenyl 2-methylpropyl (S)-methylphosphonate
-
mutant enzyme H275Y/L303T, in 50 mM CHES (pH 9.0), at 30°C
0.81
4-acetylphenyl cyclohexyl (R)-methylphosphonate
-
mutant enzyme H254G/H257W/L303T, in 50 mM CHES (pH 9.0), at 30°C
5.9
4-acetylphenyl cyclohexyl (R)-methylphosphonate
-
mutant enzyme H275Y/L303T, in 50 mM CHES (pH 9.0), at 30°C
93
4-acetylphenyl cyclohexyl (R)-methylphosphonate
-
mutant enzyme G60A, in 50 mM CHES (pH 9.0), at 30°C
150
4-acetylphenyl cyclohexyl (R)-methylphosphonate
-
mutant enzyme S308G, in 50 mM CHES (pH 9.0), at 30°C
0.14
4-acetylphenyl cyclohexyl (S)-methylphosphonate
-
mutant enzyme S308G, in 50 mM CHES (pH 9.0), at 30°C
5.1
4-acetylphenyl cyclohexyl (S)-methylphosphonate
-
mutant enzyme H275Y/L303T, in 50 mM CHES (pH 9.0), at 30°C
19
4-acetylphenyl cyclohexyl (S)-methylphosphonate
-
mutant enzyme H254G/H257W/L303T, in 50 mM CHES (pH 9.0), at 30°C
7.3
4-acetylphenyl ethyl (R)-methylphosphonate
-
mutant enzyme H275Y/L303T, in 50 mM CHES (pH 9.0), at 30°C
14
4-acetylphenyl ethyl (R)-methylphosphonate
-
mutant enzyme H254G/H257W/L303T, in 50 mM CHES (pH 9.0), at 30°C
110
4-acetylphenyl ethyl (R)-methylphosphonate
-
mutant enzyme S308G, in 50 mM CHES (pH 9.0), at 30°C
130
4-acetylphenyl ethyl (R)-methylphosphonate
-
mutant enzyme G60A, in 50 mM CHES (pH 9.0), at 30°C
150
4-acetylphenyl ethyl (R)-methylphosphonate
-
wild type enzyme, in 50 mM CHES (pH 9.0), at 30°C
110
4-acetylphenyl ethyl (S)-methylphosphonate
-
mutant enzyme G60A, in 50 mM CHES (pH 9.0), at 30°C
190
4-acetylphenyl ethyl (S)-methylphosphonate
-
mutant enzyme H254G/H257W/L303T, in 50 mM CHES (pH 9.0), at 30°C
290
4-acetylphenyl ethyl (S)-methylphosphonate
-
mutant enzyme S308G, in 50 mM CHES (pH 9.0), at 30°C
410
4-acetylphenyl ethyl (S)-methylphosphonate
-
mutant enzyme H275Y/L303T, in 50 mM CHES (pH 9.0), at 30°C
670
4-acetylphenyl ethyl (S)-methylphosphonate
-
wild type enzyme, in 50 mM CHES (pH 9.0), at 30°C
18
4-acetylphenyl propan-2-yl (R)-methylphosphonate
-
mutant enzyme H275Y/L303T, in 50 mM CHES (pH 9.0), at 30°C
100
4-acetylphenyl propan-2-yl (R)-methylphosphonate
-
wild type enzyme, in 50 mM CHES (pH 9.0), at 30°C
120
4-acetylphenyl propan-2-yl (R)-methylphosphonate
-
mutant enzyme G60A, in 50 mM CHES (pH 9.0), at 30°C
250
4-acetylphenyl propan-2-yl (R)-methylphosphonate
-
mutant enzyme S308G, in 50 mM CHES (pH 9.0), at 30°C
7.4
4-acetylphenyl propan-2-yl (S)-methylphosphonate
-
mutant enzyme G60A, in 50 mM CHES (pH 9.0), at 30°C
15
4-acetylphenyl propan-2-yl (S)-methylphosphonate
-
mutant enzyme S308G, in 50 mM CHES (pH 9.0), at 30°C
40
4-acetylphenyl propan-2-yl (S)-methylphosphonate
-
wild type enzyme, in 50 mM CHES (pH 9.0), at 30°C
92
4-acetylphenyl propan-2-yl (S)-methylphosphonate
-
mutant enzyme H254G/H257W/L303T, in 50 mM CHES (pH 9.0), at 30°C
370
4-acetylphenyl propan-2-yl (S)-methylphosphonate
-
mutant enzyme H275Y/L303T, in 50 mM CHES (pH 9.0), at 30°C
4.3
diethyl paraoxon
-
recombinant enzyme, in 20 mM Tris-HCl buffer, pH 7.4, 1 mM CaCl2, temperature not specified in the publication
5.7
diethyl paraoxon
-
in 20 mM Tris-HCl buffer, pH 7.4, 1 mM CaCl2, temperature not specified in the publication
0.007
paraoxon
pH 8.0, recombinant genetic variant G1A7
0.009
paraoxon
pH 8.0, recombinant genetic variant G1B11
0.036
paraoxon
pH 8.0, recombinant genetic variant G2C2
0.04
paraoxon
pH 8.0, recombinant genetic variant G3A5
0.11
paraoxon
pH 8.0, recombinant genetic variant G3G3
0.14
paraoxon
pH 8.0, recombinant genetic variant G3H9
0.45
paraoxon
-
in 50 mM Tris-HCl buffer, 10 mM CaCl2, pH 7.4
5.7
paraoxon
-
pH 7.4, 37°C, type A paraoxonase
10.98
paraoxon
-
pH 7.4, 37°C, type B paraoxonase
89
phenyl acetate
-
recombinant PON3
552
phenyl acetate
pH 8.0, recombinant genetic variant G1C4
562
phenyl acetate
pH 8.0, recombinant genetic variant G2D6
789
phenyl acetate
pH 8.0, recombinant genetic variant G3C9
833
phenyl acetate
pH 8.0, recombinant genetic variant G1A5
965
phenyl acetate
pH 8.0, recombinant genetic variant G2E6
1018
phenyl acetate
pH 8.0, recombinant genetic variant G3H8
1236
phenyl acetate
pH 8.0, recombinant wild-type PON1
15
sarin
-
mutant enzyme H254G/H257W/L303T, in 50 mM CHES (pH 9.0), at 30°C
39
sarin
-
mutant enzyme S308G, in 50 mM CHES (pH 9.0), at 30°C
90
sarin
-
wild type enzyme, in 50 mM CHES (pH 9.0), at 30°C
120
sarin
-
mutant enzyme G60A, in 50 mM CHES (pH 9.0), at 30°C
300
sarin
-
mutant enzyme H275Y/L303T, in 50 mM CHES (pH 9.0), at 30°C
2.2
soman
-
mutant enzyme H254G/H257W/L303T, in 50 mM CHES (pH 9.0), at 30°C
2.6
soman
-
wild type enzyme, in 50 mM CHES (pH 9.0), at 30°C
9.1
soman
-
mutant enzyme S308G, in 50 mM CHES (pH 9.0), at 30°C
25
soman
-
mutant enzyme G60A, in 50 mM CHES (pH 9.0), at 30°C
89
soman
-
mutant enzyme H275Y/L303T, in 50 mM CHES (pH 9.0), at 30°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.2 - 0.25
diethyl-paraoxon
0.11 - 11.89
dimethyl-paraoxon
0.367
parathion
pH 8.0, 25°C, enzyme administered in rats in vivo
0.283
SP-CMP
pH 8.0, 25°C, enzyme administered in mice in vivo
0.003 - 2.3
4-acetylphenyl (2R)-3,3-dimethylbutan-2-yl (R)-methylphosphonate
0.016 - 0.59
4-acetylphenyl (2R)-3,3-dimethylbutan-2-yl (S)-methylphosphonate
0.0011 - 1.7
4-acetylphenyl (2S)-3,3-dimethylbutan-2-yl (S)-methylphosphonate
1.5 - 850
4-acetylphenyl 2-methylpropyl (R)-methylphosphonate
0.099 - 180
4-acetylphenyl 2-methylpropyl (S)-methylphosphonate
0.25 - 28
4-acetylphenyl cyclohexyl (R)-methylphosphonate
0.00094 - 28
4-acetylphenyl cyclohexyl (S)-methylphosphonate
1.5 - 520
4-acetylphenyl ethyl (R)-methylphosphonate
130 - 1200
4-acetylphenyl ethyl (S)-methylphosphonate
1.8 - 580
4-acetylphenyl propan-2-yl (R)-methylphosphonate
3.1 - 110
4-acetylphenyl propan-2-yl (S)-methylphosphonate
0.00083
cyclosarin
-
in 50 mM Tris-HCl buffer, 10 mM CaCl2, pH 7.4
6.5 - 7.3
diethyl paraoxon
0.2
O-ethyl-S-[2-(diisopropylamino)ethyl]-methylphosphonothioic acid
-
in 50 mM Tris-HCl buffer, 10 mM CaCl2, pH 7.4
0.2
O-isobutyl-S-[2-(diethylamino)ethyl]methylphosphonothioic acid
-
in 50 mM Tris-HCl buffer, 10 mM CaCl2, pH 7.4
0.2
diethyl-paraoxon
pH 10.5, 25°C, recombinant PON1 wild-type enzyme
0.25
diethyl-paraoxon
pH 10.5, 25°C, recombinant PON1-hFc fusion enzyme
0.11
dimethyl-paraoxon
pH 8.0, 25°C, recombinant mutant H115W/R192I
0.18
dimethyl-paraoxon
pH 8.0, 25°C, recombinant mutant H115W/R192S
0.75
dimethyl-paraoxon
pH 8.0, 25°C, recombinant wild-type enzyme
3.23
dimethyl-paraoxon
pH 8.0, 25°C, recombinant mutant H115W/R192W
6.42
dimethyl-paraoxon
pH 8.0, 25°C, recombinant mutant H115W/R192A
6.67
dimethyl-paraoxon
pH 8.0, 25°C, recombinant mutants H115W
7.6
dimethyl-paraoxon
pH 8.0, 25°C, recombinant mutant H115W/R192N
11.89
dimethyl-paraoxon
pH 8.0, 25°C, recombinant mutant H115W/R192K
0.367
paraoxon
pH 8.0, 25°C, enzyme administered in rats in vivo
0.7
paraoxon
wild-type, pH 8.0, 25°C
4.6
paraoxon
mutant H115W/R192Q, pH 8.0, 25°C
6.6
paraoxon
mutant H115W, pH 8.0, 25°C
10.7
paraoxon
mutant H115W/R192K, pH 8.0, 25°C
0.003
4-acetylphenyl (2R)-3,3-dimethylbutan-2-yl (R)-methylphosphonate
-
mutant enzyme G60A, in 50 mM CHES (pH 9.0), at 30°C
0.058
4-acetylphenyl (2R)-3,3-dimethylbutan-2-yl (R)-methylphosphonate
-
mutant enzyme H275Y/L303T, in 50 mM CHES (pH 9.0), at 30°C
0.22
4-acetylphenyl (2R)-3,3-dimethylbutan-2-yl (R)-methylphosphonate
-
mutant enzyme H254G/H257W/L303T, in 50 mM CHES (pH 9.0), at 30°C
1.3
4-acetylphenyl (2R)-3,3-dimethylbutan-2-yl (R)-methylphosphonate
-
wild type enzyme, in 50 mM CHES (pH 9.0), at 30°C
2.3
4-acetylphenyl (2R)-3,3-dimethylbutan-2-yl (R)-methylphosphonate
-
mutant enzyme S308G, in 50 mM CHES (pH 9.0), at 30°C
0.016
4-acetylphenyl (2R)-3,3-dimethylbutan-2-yl (S)-methylphosphonate
-
mutant enzyme H275Y/L303T, in 50 mM CHES (pH 9.0), at 30°C
0.13
4-acetylphenyl (2R)-3,3-dimethylbutan-2-yl (S)-methylphosphonate
-
mutant enzyme H254G/H257W/L303T, in 50 mM CHES (pH 9.0), at 30°C
0.2
4-acetylphenyl (2R)-3,3-dimethylbutan-2-yl (S)-methylphosphonate
-
wild type enzyme, in 50 mM CHES (pH 9.0), at 30°C
0.49
4-acetylphenyl (2R)-3,3-dimethylbutan-2-yl (S)-methylphosphonate
-
mutant enzyme S308G, in 50 mM CHES (pH 9.0), at 30°C
0.59
4-acetylphenyl (2R)-3,3-dimethylbutan-2-yl (S)-methylphosphonate
-
mutant enzyme G60A, in 50 mM CHES (pH 9.0), at 30°C
0.0011
4-acetylphenyl (2S)-3,3-dimethylbutan-2-yl (S)-methylphosphonate
-
mutant enzyme G60A, in 50 mM CHES (pH 9.0), at 30°C
0.0032
4-acetylphenyl (2S)-3,3-dimethylbutan-2-yl (S)-methylphosphonate
-
wild type enzyme, in 50 mM CHES (pH 9.0), at 30°C
0.0067
4-acetylphenyl (2S)-3,3-dimethylbutan-2-yl (S)-methylphosphonate
-
mutant enzyme S308G, in 50 mM CHES (pH 9.0), at 30°C
0.25
4-acetylphenyl (2S)-3,3-dimethylbutan-2-yl (S)-methylphosphonate
-
mutant enzyme H275Y/L303T, in 50 mM CHES (pH 9.0), at 30°C
1.7
4-acetylphenyl (2S)-3,3-dimethylbutan-2-yl (S)-methylphosphonate
-
mutant enzyme H254G/H257W/L303T, in 50 mM CHES (pH 9.0), at 30°C
1.5
4-acetylphenyl 2-methylpropyl (R)-methylphosphonate
-
mutant enzyme H254G/H257W/L303T, in 50 mM CHES (pH 9.0), at 30°C
13
4-acetylphenyl 2-methylpropyl (R)-methylphosphonate
-
mutant enzyme H275Y/L303T, in 50 mM CHES (pH 9.0), at 30°C
180
4-acetylphenyl 2-methylpropyl (R)-methylphosphonate
-
mutant enzyme S308G, in 50 mM CHES (pH 9.0), at 30°C
760
4-acetylphenyl 2-methylpropyl (R)-methylphosphonate
-
mutant enzyme G60A, in 50 mM CHES (pH 9.0), at 30°C
850
4-acetylphenyl 2-methylpropyl (R)-methylphosphonate
-
wild type enzyme, in 50 mM CHES (pH 9.0), at 30°C
0.099
4-acetylphenyl 2-methylpropyl (S)-methylphosphonate
-
mutant enzyme G60A, in 50 mM CHES (pH 9.0), at 30°C
9.5
4-acetylphenyl 2-methylpropyl (S)-methylphosphonate
-
mutant enzyme S308G, in 50 mM CHES (pH 9.0), at 30°C
34
4-acetylphenyl 2-methylpropyl (S)-methylphosphonate
-
wild type enzyme, in 50 mM CHES (pH 9.0), at 30°C
73
4-acetylphenyl 2-methylpropyl (S)-methylphosphonate
-
mutant enzyme H275Y/L303T, in 50 mM CHES (pH 9.0), at 30°C
180
4-acetylphenyl 2-methylpropyl (S)-methylphosphonate
-
mutant enzyme H254G/H257W/L303T, in 50 mM CHES (pH 9.0), at 30°C
0.25
4-acetylphenyl cyclohexyl (R)-methylphosphonate
-
mutant enzyme H254G/H257W/L303T, in 50 mM CHES (pH 9.0), at 30°C
1.9
4-acetylphenyl cyclohexyl (R)-methylphosphonate
-
mutant enzyme H275Y/L303T, in 50 mM CHES (pH 9.0), at 30°C
16
4-acetylphenyl cyclohexyl (R)-methylphosphonate
-
wild type enzyme, in 50 mM CHES (pH 9.0), at 30°C
21
4-acetylphenyl cyclohexyl (R)-methylphosphonate
-
mutant enzyme G60A, in 50 mM CHES (pH 9.0), at 30°C
28
4-acetylphenyl cyclohexyl (R)-methylphosphonate
-
mutant enzyme S308G, in 50 mM CHES (pH 9.0), at 30°C
0.00094
4-acetylphenyl cyclohexyl (S)-methylphosphonate
-
mutant enzyme G60A, in 50 mM CHES (pH 9.0), at 30°C
0.021
4-acetylphenyl cyclohexyl (S)-methylphosphonate
-
wild type enzyme, in 50 mM CHES (pH 9.0), at 30°C
0.1
4-acetylphenyl cyclohexyl (S)-methylphosphonate
-
mutant enzyme S308G, in 50 mM CHES (pH 9.0), at 30°C
5.8
4-acetylphenyl cyclohexyl (S)-methylphosphonate
-
mutant enzyme H275Y/L303T, in 50 mM CHES (pH 9.0), at 30°C
28
4-acetylphenyl cyclohexyl (S)-methylphosphonate
-
mutant enzyme H254G/H257W/L303T, in 50 mM CHES (pH 9.0), at 30°C
1.5
4-acetylphenyl ethyl (R)-methylphosphonate
-
mutant enzyme H254G/H257W/L303T, in 50 mM CHES (pH 9.0), at 30°C
2.4
4-acetylphenyl ethyl (R)-methylphosphonate
-
mutant enzyme H275Y/L303T, in 50 mM CHES (pH 9.0), at 30°C
75
4-acetylphenyl ethyl (R)-methylphosphonate
-
mutant enzyme S308G, in 50 mM CHES (pH 9.0), at 30°C
490
4-acetylphenyl ethyl (R)-methylphosphonate
-
wild type enzyme, in 50 mM CHES (pH 9.0), at 30°C
520
4-acetylphenyl ethyl (R)-methylphosphonate
-
mutant enzyme G60A, in 50 mM CHES (pH 9.0), at 30°C
130
4-acetylphenyl ethyl (S)-methylphosphonate
-
mutant enzyme G60A, in 50 mM CHES (pH 9.0), at 30°C
150
4-acetylphenyl ethyl (S)-methylphosphonate
-
mutant enzyme S308G, in 50 mM CHES (pH 9.0), at 30°C
160
4-acetylphenyl ethyl (S)-methylphosphonate
-
mutant enzyme H275Y/L303T, in 50 mM CHES (pH 9.0), at 30°C
220
4-acetylphenyl ethyl (S)-methylphosphonate
-
mutant enzyme H254G/H257W/L303T, in 50 mM CHES (pH 9.0), at 30°C
1200
4-acetylphenyl ethyl (S)-methylphosphonate
-
wild type enzyme, in 50 mM CHES (pH 9.0), at 30°C
1.8
4-acetylphenyl propan-2-yl (R)-methylphosphonate
-
mutant enzyme H254G/H257W/L303T, in 50 mM CHES (pH 9.0), at 30°C
2.5
4-acetylphenyl propan-2-yl (R)-methylphosphonate
-
mutant enzyme H275Y/L303T, in 50 mM CHES (pH 9.0), at 30°C
110
4-acetylphenyl propan-2-yl (R)-methylphosphonate
-
mutant enzyme S308G, in 50 mM CHES (pH 9.0), at 30°C
520
4-acetylphenyl propan-2-yl (R)-methylphosphonate
-
mutant enzyme G60A, in 50 mM CHES (pH 9.0), at 30°C
580
4-acetylphenyl propan-2-yl (R)-methylphosphonate
-
wild type enzyme, in 50 mM CHES (pH 9.0), at 30°C
3.1
4-acetylphenyl propan-2-yl (S)-methylphosphonate
-
mutant enzyme S308G, in 50 mM CHES (pH 9.0), at 30°C
5.9
4-acetylphenyl propan-2-yl (S)-methylphosphonate
-
mutant enzyme H254G/H257W/L303T, in 50 mM CHES (pH 9.0), at 30°C
6.2
4-acetylphenyl propan-2-yl (S)-methylphosphonate
-
mutant enzyme G60A, in 50 mM CHES (pH 9.0), at 30°C
27
4-acetylphenyl propan-2-yl (S)-methylphosphonate
-
wild type enzyme, in 50 mM CHES (pH 9.0), at 30°C
110
4-acetylphenyl propan-2-yl (S)-methylphosphonate
-
mutant enzyme H275Y/L303T, in 50 mM CHES (pH 9.0), at 30°C
6.5
diethyl paraoxon
-
recombinant enzyme, in 20 mM Tris-HCl buffer, pH 7.4, 1 mM CaCl2, temperature not specified in the publication
7.3
diethyl paraoxon
-
in 20 mM Tris-HCl buffer, pH 7.4, 1 mM CaCl2, temperature not specified in the publication
0.02167
paraoxon
-
PON1/human phosphate binding protein (1:1), in 50 mM Tris buffer, 1 mM NaCl, pH 8.0 at 25°C
0.3
paraoxon
-
in 50 mM Tris-HCl buffer, 10 mM CaCl2, pH 7.4
0.33
paraoxon
-
PON1/human phosphate binding protein (9:1), in 50 mM Tris buffer, 1 mM NaCl, pH 8.0 at 25°C
1.11
paraoxon
-
isozyme 192Q, in 100 mM Tris-HCl (pH 8.5), 1 mM CaCl2, 37°C
3.67
paraoxon
-
isozyme 192R, in 100 mM Tris-HCl (pH 8.5), 1 mM CaCl2, 37°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
C284A
mutant with 20fold reduced paraoxonase activity
C284D
no enzymic activity
D183N
the mutant disfavors paraoxon binding due to its charged nature and possible electrostatic repulsion with the phosphate group of paraoxon
D269E
no enzymic activity
E313A
slightly decreased activity
E314A
enzymic activity similar to wild-type
G11A
slightly enhanced activity with phenyl acetate and paraoxon
G11C
slightly enhanced activity with phenyl acetate and paraoxon
G11S
slightly enhanced activity with phenyl acetate and paraoxon
H115A
activity with paraoxon is 167% of wild-type activity, activity with 7-diethylphosphoro-3-cyanocoumarin is 119% of wild-type activity
H115Q
activity with paraoxon is 32% of wild-type activity, activity with 7-diethylphosphoro-3-cyanocoumarin is 25% of wild-type activity
H115W/R192A
site-directed mutagenesis, the mutant shows altered substrate specificity and activity compared to the wild-type, overview
H115W/R192D
site-directed mutagenesis, the mutant shows altered substrate specificity and activity compared to the wild-type, overview
H115W/R192E
site-directed mutagenesis, the mutant shows altered substrate specificity and activity compared to the wild-type, overview
H115W/R192F
site-directed mutagenesis, the mutant shows altered substrate specificity and activity compared to the wild-type, overview
H115W/R192G
site-directed mutagenesis, the mutant shows altered substrate specificity and activity compared to the wild-type, overview
H115W/R192H
site-directed mutagenesis, the mutant shows altered substrate specificity and activity compared to the wild-type, overview
H115W/R192I
site-directed mutagenesis, the mutant shows altered substrate specificity and activity compared to the wild-type, overview
H115W/R192K/A137T
site-directed mutagenesis, the mutant shows altered substrate specificity compared to wild-type
H115W/R192K/A137T/D94H/S211T
site-directed mutagenesis, the mutant shows altered substrate specificity compared to wild-type
H115W/R192K/A137T/L130F
site-directed mutagenesis, the mutant shows altered substrate specificity compared to wild-type
H115W/R192K/A137T/M127I/D263H
site-directed mutagenesis, the mutant shows altered substrate specificity compared to wild-type
H115W/R192K/A137T/S81R/P165A
site-directed mutagenesis, the mutant shows altered substrate specificity compared to wild-type
H115W/R192L
site-directed mutagenesis, the mutant shows altered substrate specificity and activity compared to the wild-type, overview
H115W/R192M
site-directed mutagenesis, the mutant shows altered substrate specificity and activity compared to the wild-type, overview
H115W/R192N
site-directed mutagenesis, the mutant shows altered substrate specificity and activity compared to the wild-type, overview
H115W/R192P
site-directed mutagenesis, the mutant shows altered substrate specificity and activity compared to the wild-type, overview
H115W/R192R
site-directed mutagenesis, the mutant shows altered substrate specificity and activity compared to the wild-type, overview
H115W/R192S
site-directed mutagenesis, the mutant shows altered substrate specificity and activity compared to the wild-type, overview
H115W/R192T
site-directed mutagenesis, the mutant shows altered substrate specificity and activity compared to the wild-type, overview
H115W/R192V
site-directed mutagenesis, the mutant shows altered substrate specificity and activity compared to the wild-type, overview
H115W/R192W
site-directed mutagenesis, the mutant shows altered substrate specificity and activity compared to the wild-type, overview
H115W/R192Y
site-directed mutagenesis, the mutant shows altered substrate specificity and activity compared to the wild-type, overview
H134Q
activity with paraoxon is 602% of wild-type activity, activity with 7-diethylphosphoro-3-cyanocoumarin is 38% of wild-type activity
H134W
no enzymic activity
H134Y
no enzymic activity
H184Q
activity with paraoxon is 8.9% of wild-type activity, activity with 7-diethylphosphoro-3-cyanocoumarin is 7.9% of wild-type activity
H184T
activity with paraoxon is 9.3% of wild-type activity, activity with 7-diethylphosphoro-3-cyanocoumarin is 2.7% of wild-type activity
H285D
no enzymic activity
H285Q
activity with paraoxon is 13% of wild-type activity, activity with 7-diethylphosphoro-3-cyanocoumarin is 4.3% of wild-type activity
H285S
activity with paraoxon is 53% of wild-type activity, activity with 7-diethylphosphoro-3-cyanocoumarin is 25% of wild-type activity
H285Y
no enzymic activity
L69G/S111T/H115W/H134R/R192K/F222S/T332S
mutant designed for expression in Escherichia coli in soluble and active form. Mutants is more than 20fold better in hydrolyzing paraoxon substrate compared to wild-type and more than 100fold better in hydrolsis of diisopropyl fluorophosphate
L69V
the mutant shows a 4-16fold increase in PON1 activity compared to the wild type enzyme
L69V/V369A
the mutant shows increased paraoxon binding affinity compared to the wild type enzyme
N133S
enzymic activity similar to wild-type
N168E
no enzymic activity
N224A
no enzymic activity
R192A
site-directed mutagenesis
R192E
natural polymorphism, polymorphism at position 192 plays an important role in determining the substrate specificity and catalytic efficiency of the enzyme
R192I
site-directed mutagenesis
R192K
site-directed mutagenesis
R192V
site-directed mutagenesis
S193P
the mutation increases phosphotriesterase activity of PON1
V304A
no enzymic activity
V346A
the mutant shows a 4-16fold increase in PON1 activity compared to the wild type enzyme
C283A
-
retains enzymatic activity, not inactivated by p-hydroxymercuribenzoate
C283S
-
retains enzymatic activity, not inactivated by p-hydroxymercuribenzoate
C284D
site-directed mutagenesis, inactive mutant
D269E
site-directed mutagenesis, inactive mutant
D54N
site-directed mutagenesis, inactive mutant
E313A
site-directed mutagenesis, the mutant enzyme shows altered kinetics compared to the wild-type enzyme
E314A
site-directed mutagenesis, the mutant enzyme shows slightly altered kinetics compared to the wild-type enzyme
F132G
-
the mutant shows decreased catalytic efficiency compared to the wild type enzyme
F222A
site-directed mutagenesis, inactive mutant
F222D
site-directed mutagenesis, inactive mutant
F222Y
site-directed mutagenesis, the mutant enzyme shows altered kinetics compared to the wild-type enzyme
G11A
site-directed mutagenesis, the mutant enzyme shows slightly altered kinetics compared to the wild-type enzyme
G11C
site-directed mutagenesis, the mutant enzyme shows slightly altered kinetics compared to the wild-type enzyme
G11S
site-directed mutagenesis, the mutant enzyme shows slightly altered kinetics compared to the wild-type enzyme
G60A
-
the mutant shows increased catalytic efficiency with sarin and soman compared to the wild type enzyme
H114N
-
catalytically inactive
H115W
site-directed mutagenesis, the mutant enzyme shows reduced activity and altered kinetics compared to the wild-type enzyme
H115W/N133S
site-directed mutagenesis, the mutant enzyme shows reduced activity and altered kinetics compared to the wild-type enzyme
H115W/R192K
the mutant enzyme exhibits considerably increased organophosphate-hydrolyzing activity compared to the wild type enzyme
H133N
-
catalytically inactive
H134W
site-directed mutagenesis, inactive mutant
H134Y
site-directed mutagenesis, inactive mutant
H254Q/H257F
-
the mutant shows increased catalytic efficiency compared to the wild type enzyme
H257Y/L303T
-
the mutant shows decreased catalytic efficiency compared to the wild type enzyme
H284N
-
catalytically inactive
H285D
site-directed mutagenesis, inactive mutant
H285Y
site-directed mutagenesis, inactive mutant
I106A/F132A/H257Y
-
the mutant shows decreased catalytic efficiency compared to the wild type enzyme
I106A/H257Y/S308A
-
the mutant shows decreased catalytic efficiency compared to the wild type enzyme
I106G
-
the mutant shows decreased catalytic efficiency compared to the wild type enzyme
I106G/F132G/H257Y
-
the mutant shows decreased catalytic efficiency compared to the wild type enzyme
I106G/H257Y
-
the mutant shows decreased catalytic efficiency compared to the wild type enzyme
L69F
site-directed mutagenesis, inactive mutant
N133S
site-directed mutagenesis, the mutant enzyme shows slightly altered kinetics compared to the wild-type enzyme
N168E
site-directed mutagenesis, inactive mutant
N224A
site-directed mutagenesis, inactive mutant
R180T
the mutant enzyme exhibits 180fold increased ethyl paraoxon-hydrolyzing activity compared to the wild type enzyme
R460T
the mutant enzyme exhibits 23fold increased ethyl paraoxon-hydrolyzing activity and 340fold increased diisopropylfluorophosphate-hydrolyzing activity compared to the wild type enzyme
R478T
the mutant enzyme exhibits 8fold increased ethyl paraoxon-hydrolyzing activity compared to the wild type enzyme
R784T
the mutant enzyme exhibits 3fold increased ethyl paraoxon-hydrolyzing activity compared to the wild type enzyme
R789T
the mutant enzyme exhibits 15fold increased ethyl paraoxon-hydrolyzing activity compared to the wild type enzyme
S308G
-
the mutant shows decreased catalytic efficiency compared to the wild type enzyme
V304A
site-directed mutagenesis, inactive mutant
F222D
no enzymic activity
F222D
the mutation abolishes both esterase and PON activity of PON1
F222Y
hydrolysis of phenyl acetate, but not of paraoxon
F222Y
increased activity with phenyl acetate, no activity with paraoxon
F222Y
the mutation abolishes the PON activity of PON1 but retains the esterase activity with a 1.5fold increase in KM for phenyl acetate
H115W
no enzymic activity with phenyl acetate, increased activity with paraoxon
H115W
no hydrolysis of phenyl acetate, but hydrolysis of paraoxon. Phenyl acetate can act as an inhibitor
H115W
activity with paraoxon is 195% of wild-type activity, activity with 7-diethylphosphoro-3-cyanocoumarin is 234% of wild-type activity
H115W
the mutant shows a 2fold increase in PON1 activity compared to the wild type enzyme
H115W
significant increase in the rate of catalysis, no effect on the affinity of the substrate
H115W/N133S
no enzymic activity with phenyl acetate, slightly decreased activity with paraoxon
H115W/N133S
no hydrolysis of phenyl acetate, but hydrolysis of paraoxon
H115W/R192K
site-directed mutagenesis
H115W/R192K
further increases in the paraoxon hydrolyzing activity of the enzyme
H115W/R192K
site-directed mutagenesis, the mutant shows altered substrate specificity and activity compared to the wild-type, overview
H115W/R192K
site-directed mutagenesis, the mutant shows altered substrate specificity compared to wild-type
H115W/R192Q
mutation R192Q eleiminates the effect of mutation H115W
H115W/R192Q
site-directed mutagenesis, the mutant shows altered substrate specificity and activity compared to the wild-type, overview
L55M
naturally occuring polymorphism, allele frequency in relation to exposure of individuals to organophosphates, overview
L55M
the mutant shows low enzymatic activity
L55M
the polymorphism accounts for 73% of PON1 activity
L55M
natural polymorphism, the polymorphism at the 55th position of h-PON1 does not affect the catalytic properties of the enzyme
Q192R
naturally occuring polymorphism, allele frequency in relation to exposure of individuals to organophosphates, overview
Q192R
a naturally occuring polymorphism, 192QQ, 192RR or 192QR, that reduces PON1 activity and increases the risk of ischemic stroke, genotyping and phenotyping, allele frequency, the paraoxonase/arylesterase activity ratio is unaltered
Q192R
the homozygote phenotype has significant lower PON1 activity towards paraoxon and diazoxon than the wild type enzyme
Q192R
the mutant hydrolyzes paraoxon approximately 9times as efficiently as the wild type enzyme and is significantly more efficient in hydrolyzing chlorpyrifos oxon
Q192R
the mutant hydrolyzes paraoxon with a high enzyme activity
Q192R
the mutant shows lower Vmax and kcat/Km values for soman and sarin than the wild type enzyme
Q192R
the mutation is associated with sporadic amyotrophic lateral sclerosis
Q192R
the polymorphism accounts for 69% of PON1 activity, the 192RR genotype carriers have the highest PON1 activity, whereas the the 192QQ genotype carriers have the lowest activity, with the heterozygote 192Q/R having intermediate activity
Q192R
there are substrate-dependent differences among PON1 Q192R isoforms, the Q variant has a higher diazoxonase activity, whereas paraoxonase activity predominates in the R variant
R192Q
site-directed mutagenesis
R192Q
a naturally occuring polymorphism, 192QQ, 192RR or 192QR, that reduces PON1 activity and increases the risk of ischemic stroke, genotyping and phenotyping, allele frequency, the paraoxonase/arylesterase activity ratio is unaltered
R192Q
the polymorphic residue R192Q interacts with the leaving group of paraoxon, suggesting it plays an important role in the proper positioning of this substrate in the active site
Q192R
-
the mutant exhibits significantly lower homocysteine-thiolactone/creatinine levels and has 2.6 and 3.3fold greater catalytic efficiency with homocysteine-thiolactone and paraoxon, respectively, than the wild type enzyme
Q192R
-
the mutation is related to vascular disease and variation in the enzyme activity
additional information
the presence of a (His)6-tag at the N-terminus and at both the N- and C-termini decreases the enzymatic activity of the recombinant protein. The activity is unaffected by the presence of a (His)6-tag at its C-terminus
additional information
-
the presence of a (His)6-tag at the N-terminus and at both the N- and C-termini decreases the enzymatic activity of the recombinant protein. The activity is unaffected by the presence of a (His)6-tag at its C-terminus
additional information
development of a recombinant production method for the enzyme in Escherichia coli, which can be used for the industrial scale production of rh-PON1 enzymes. The catalytic properties of the refolded enzymes are similar to their soluble counterparts
additional information
-
development of a recombinant production method for the enzyme in Escherichia coli, which can be used for the industrial scale production of rh-PON1 enzymes. The catalytic properties of the refolded enzymes are similar to their soluble counterparts
additional information
generation of wild-type-like-G3C9-derived PON1 variants 2D8, IIG1, VIID2 and PG11
additional information
-
h-PON1 is a polymorphic enzyme. A random mutagenesis approach is used to increase the organophosphate (OP)-hydrolyzing activity of recombinant enzyme h-PON1. The mutants not only show a 10-340fold increased OP-hydrolyzing activity against different OP substrates but also exhibit differential lactonase and arylesterase activities, molecular docking studies, overview. Random mutagenesis using Escherichia coli XL-1 Red mutator strain. All mutations result in a considerable decrease in the delta-valerolactone-hydrolyzing activity of the enzyme
additional information
h-PON1 is a polymorphic enzyme. A random mutagenesis approach is used to increase the organophosphate (OP)-hydrolyzing activity of recombinant enzyme h-PON1. The mutants not only show a 10-340fold increased OP-hydrolyzing activity against different OP substrates but also exhibit differential lactonase and arylesterase activities, molecular docking studies, overview. Random mutagenesis using Escherichia coli XL-1 Red mutator strain. All mutations result in a considerable decrease in the delta-valerolactone-hydrolyzing activity of the enzyme
additional information
nanocapsulation of enzyme into enzyme-polyelectrolyte complexes leads to its expected stabilisation and significant improvement of Km and Ksi with methylphosphonic acid
additional information
the catalytic efficiency of the recombinant human paraoxonase 1 fused to human immunoglobulin Fc domain, i.e. recombinant PON1-hFc, towards diisopropyl fluorophosphate (DFP) and paraoxon hydrolysis is 1.63 and 1.24fold higher, respectively, than the recombinant human wild-type PON1
additional information
-
analysis of PON1 polymorphisms, e.g. at residue Q192R, overview
additional information
-
naturally occurring polymorphism Q192R
additional information
-
naturally occurring polymorphism Q192R
additional information
-
increased activity and lifetime of OPH immobilized using layer-by-layer nano self-assembly on silicon microchannels, the polycation used is poly(ethylenimine), the polyanion used is poly(styrenesulfonate), method development and optimization, overview
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Gonzalo, M.C.; Gil, F.; Hernandez, A.F.; Rodrigo, L.; Villanueva, E.; Pla, A.
Human liver paraoxonase (PON1): subcellular distribution and characterization
J. Biochem. Mol. Toxicol.
12
61-69
1998
Homo sapiens
brenda
Reiner, E.; Simeon-Rudolf, V.; Skrinjaric-Spoljar, M.
Catalytic properties and distribution profiles of paraoxonase and cholinesterase phenotypes in human sera
Toxicol. Lett.
82/83
447-452
1995
Homo sapiens
brenda
Aviram, M.; Rosenblatt, M.; Bisgaier, C.L.; Newton, R.S.; Primo-Parmo, S.L.; La Du, B.N.
Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase
J. Clin. Invest.
101
1581-1590
1998
Homo sapiens
brenda
Hernandez, A.F.; Pla, A.; Valenzuela, A.; Gil, F.; Villanueva, E.
Characterization of paraoxonase activity in pericardial fluid: usefulness as a marker of coronary disease
Chem. Biol. Interact.
87
173-177
1993
Homo sapiens
brenda
Gan, K.N.; Smolen, A.; Eckerson, H.W.; La Du, B.N.
Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities
Drug Metab. Dispos.
19
100-106
1991
Homo sapiens
brenda
Smolen, A.; Eckerson, H.W.; Gan, K.N.; Hailat, N.; La Du, B.N.
Characteristics of the genetically determined allozymic forms of human serum paraoxonase/arylesterase
Drug Metab. Dispos.
19
107-112
1991
Homo sapiens
brenda
Haagen, L.; Brock, A.
A new automated method for phenotyping arylesterase (EC 3.1.1.2) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate
Eur. J. Clin. Chem. Clin. Biochem.
30
391-395
1992
Homo sapiens
brenda
Nishio, E.; Watanabe, Y.
Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme s free thiols
Biochem. Biophys. Res. Commun.
236
289-293
1997
Homo sapiens
brenda
Tanaka-Kawai, H.; Yomoda, S.
Molecular weight and substrate characteristics of human serum arylesterase following purification by immuno-affinity chromatography
Clin. Chim. Acta
215
127-138
1993
Homo sapiens
brenda
Furlong, C.E.; Richter, R.J.; Chapline, C.; Crabb, J.W.
Purification of rabbit and human serum paraoxonase
Biochemistry
30
10133-10140
1991
Oryctolagus cuniculus, Homo sapiens
brenda
Mackness, M.I.; Thompson, H.M.; Hardy, A.R.; Walker, C.H.
Distinction between A-esterases and arylesterases. Implications for esterase classification
Biochem. J.
245
293-296
1987
Bos taurus, Felis catus, Homo sapiens, Hydrochoerus hydrochaeris, Meles taxus, Mus musculus, no activity in aves, Rattus norvegicus, Sus scrofa
brenda
Mackness, M.I.; Arrol, S.; Durrington, P.N.
Substrate specificity of human serum paraoxonase
Biochem. Soc. Trans.
19
304S
1991
Homo sapiens
brenda
Hassett, C.; Richter, R.J.; Humbert, R.; Chapline, C.; Crabb, J.W.; Omiecinski, C.J.; Furlong, C.E.
Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence
Biochemistry
30
10141-10149
1991
Oryctolagus cuniculus, Homo sapiens
brenda
La Du, B.N.; Adkins, S.; Kuo, C.L.; Lipsig, D.
Studies on human serum paraoxonase/arylesterase
Chem. Biol. Interact.
87
25-34
1993
Homo sapiens
brenda
Pellin, M.C.; Moretto, A.; Lotti, M.; Vilanova, E.
Distribution and some biochemical properties of rat paraoxonase activity
Neurotoxicol. Teratol.
12
611-614
1990
Homo sapiens, Rattus norvegicus
brenda
Josse, D.; Ebel, C.; Stroebel, D.; Fontaine, A.; Borges, F.; Echalier, A.; Baud, D.; Renault, F.; le Maire, M.; Chabrieres, E.; Masson, P.
Oligomeric states of the detergent-solubilized human serum paraoxonase (PON1)
J. Biol. Chem.
277
33386-33397
2002
Homo sapiens
brenda
Deakin, S.; Leviev, I.; Gomaraschi, M.; Calabresi, L.; Franceschini, G.; James, R.W.
Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism
J. Biol. Chem.
277
4301-4308
2002
Homo sapiens
brenda
Ng, C.J.; Wadleigh, D.J.; Gangopadhyay, A.; Hama, S.; Grijalva, V.R.; Navab, M.; Fogelman, A.M.; Reddy, S.T.
Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein
J. Biol. Chem.
276
44444-44449
2001
Homo sapiens
brenda
Sorenson, R.C.; Primo-Parmo, S.L.; Kuo, C.L.; Adkins, S.; Lockridge, O.; La Du, B.N.
Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase
Proc. Natl. Acad. Sci. USA
92
7187-7191
1995
Homo sapiens
brenda
Costa, L.G.; Li, W.F.; Richter, R.J.; Shih, D.M.; Lusis, A.; Furlong, C.E.
The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism
Chem. Biol. Interact.
119-120
429-438
1999
Homo sapiens
brenda
Kuo, C.L.; La Du, B.N.
Comparison of purified human and rabbit serum paraoxonases
Drug Metab. Dispos.
23
935-944
1995
Oryctolagus cuniculus, Homo sapiens
brenda
La Du, B.N.; Billecke, S.; Hsu, C.; Haley, R.W.; Broomfield, C.A.
Serum paraoxonase (PON1) isozymes: the quantitative analysis of isozymes affecting individual sensitivity to environmental chemicals
Drug Metab. Dispos.
29
566-569
2001
Homo sapiens (P27169)
brenda
Serhatlioglu, S.; Gursu, M.F.; Gulcu, F.; Canatan, H.; Godekmerdan, A.
Levels of paraoxonase and arylesterase activities and malondialdehyde in workers exposed to ionizing radiation
Cell Biochem. Funct.
21
371-375
2003
Homo sapiens
brenda
Ahmed, Z.; Babaei, S.; Maguire, G.F.; Draganov, D.; Kuksis, A.; La Du, B.N.; Connelly, P.W.
Paraoxonase-1 reduces monocyte chemotaxis and adhesion to endothelial cells due to oxidation of palmitoyl, linoleoyl glycerophosphorylcholine
Cardiovasc. Res.
57
225-231
2003
Homo sapiens
brenda
Ahmed, Z.; Ravandi, A.; Maguire, G.F.; Emili, A.; Draganov, D.; La Du, B.N.; Kuksis, A.; Connelly, P.W.
Multiple substrates for paraoxonase-1 during oxidation of phosphatidylcholine by peroxynitrite
Biochem. Biophys. Res. Commun.
290
391-396
2002
Homo sapiens
brenda
Leviev, I.; Deakin, S.; James, R.W.
Decreased stability of the M54 isoform of paraoxonase as a contributory factor to variations in human serum paraoxonase concentrations
J. Lipid Res.
42
528-535
2001
Homo sapiens
brenda
Doorn, J.A.; Sorenson, R.C.; Billecke, S.S.; Hsu, C.; La Du, B.N.
Evidence that several conserved histidine residues are required for hydrolytic activity of human paraoxonase/arylesterase
Chem. Biol. Interact.
119-120
235-241
1999
Homo sapiens
brenda
Costa, L.G.; Cole, T.B.; Furlong, C.E.
Polymorphisms of paraoxonase (PON1) and their significance in clinical toxicology of organophosphates
J. Toxicol. Clin. Toxicol.
41
37-45
2003
Homo sapiens
brenda
Kuo, C.L.; La Du, B.N.
Calcium binding by human and rabbit serum paraoxonases. Structural stability and enzymic activity
Drug Metab. Dispos.
26
653-660
1998
Oryctolagus cuniculus, Homo sapiens
brenda
Billecke, S.; Draganov, D.; Counsell, R.; Stetson, P.; Watson, C.; Hsu, C.; La Du, B.N.
Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters
Drug Metab. Dispos.
28
1335-1342
2000
Homo sapiens (P27169), Homo sapiens
brenda
Brushia, R.J.; Forte, T.M.; Oda, M.N.; La Du, B.N.; Bielicki, J.K.
Baculovirus-mediated expression and purification of human serum paraoxonase 1A
J. Lipid Res.
42
951-958
2001
Homo sapiens
brenda
Soukharev, S.; Hammond, D.J.
A fluorogenic substrate for detection of organophosphatase activity
Anal. Biochem.
327
140-148
2004
Homo sapiens
brenda
Gaidukov, L.; Tawfik, D.S.
High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I
Biochemistry
44
11843-11854
2005
Homo sapiens (P27169)
brenda
Khersonsky, O.; Tawfik, D.S.
Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase
Biochemistry
44
6371-6382
2005
Homo sapiens (P27169)
brenda
Sinan, S.; Kockar, F.; Gencer, N.; Yildirim, H.; Arslan, O.
Amphenicol and macrolide derived antibiotics inhibit paraoxonase enzyme activity in human serum and human hepatoma cells (HepG2) in vitro
Biochemistry (Moscow)
71
46-50
2006
Homo sapiens
brenda
Yeung, D.T.; Josse, D.; Nicholson, J.D.; Khanal, A.; McAndrew, C.W.; Bahnson, B.J.; Lenz, D.E.; Cerasoli, D.M.
Structure/function analyses of human serum paraoxonase (HuPON1) mutants designed from a DFPase-like homology model
Biochim. Biophys. Acta
1702
67-77
2004
Homo sapiens, Homo sapiens (P27169)
brenda
Bergmeier, C.; Siekmeier, R.; Gross, W.
Distribution spectrum of paraoxonase activity in HDL fractions
Clin. Chem.
50
2309-2315
2004
Homo sapiens
brenda
Costa, L.G.; Cole, T.B.; Vitalone, A.; Furlong, C.E.
Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity
Clin. Chim. Acta
352
37-47
2005
Homo sapiens
brenda
Yeung, D.T.; Lenz, D.E.; Cerasoli, D.M.
Analysis of active-site amino-acid residues of human serum paraoxonase using competitive substrates
FEBS J.
272
2225-2230
2005
Homo sapiens (P27169), Homo sapiens
brenda
James, R.W.; Deakin, S.P.
The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity
Free Radic. Biol. Med.
37
1986-1994
2004
Homo sapiens, Mus musculus
brenda
Khersonsky, O.; Tawfik, D.S.
The histidine 115-histidine 134 dyad mediates the lactonase activity of mammalian serum paraoxonases
J. Biol. Chem.
281
7649-7656
2006
Homo sapiens (P27169)
brenda
Draganov, D.I.; Teiber, J.F.; Speelman, A.; Osawa, Y.; Sunahara, R.; La Du, B.N.
Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities
J. Lipid Res.
46
1239-1247
2005
Homo sapiens (P27169), Homo sapiens (Q15166)
brenda
Briseno-Roa, L.; Hill, J.; Notman, S.; Sellers, D.; Smith, A.P.; Timperley, C.M.; Wetherell, J.; Williams, N.H.; Williams, G.R.; Fersht, A.R.; Griffiths, A.D.
Analogues with fluorescent leaving groups for screening and selection of enzymes that efficiently hydrolyze organophosphorus nerve agents
J. Med. Chem.
49
246-255
2006
Brevundimonas diminuta, Homo sapiens
brenda
Harel, M.; Aharoni, A.; Gaidukov, L.; Brumshtein, B.; Khersonsky, O.; Meged, R.; Dvir, H.; Ravelli, R.B.G.; McCarthy, A.; Toker, L.; Silman, I.; Sussman, J.L.; Tawfik, D.S.
Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes
Nat. Struct. Mol. Biol.
11
412-419
2004
Homo sapiens (P27169)
brenda
Aharoni, A.; Gaidukov, L.; Yagur, S.; Toker, L.; Silman, I.; Tawfik, D.S.
Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization
Proc. Natl. Acad. Sci. USA
101
482-487
2004
Homo sapiens (P27169), Homo sapiens (Q15166), Mus musculus (Q62087), Oryctolagus cuniculus (Q9BGN0)
brenda
Kiderlen, D.; Eyer, P.; Worek, F.
Formation and disposition of diethylphosphoryl-obidoxime, a potent anticholinesterase that is hydrolyzed by human paraoxonase (PON1)
Biochem. Pharmacol.
69
1853-1867
2005
Homo sapiens
brenda
Costa, L.G.; Vitalone, A.; Cole, T.B.; Furlong, C.E.
Modulation of paraoxonase (PON1) activity
Biochem. Pharmacol.
69
541-550
2005
Homo sapiens
brenda
Pasca, S.P.; Nemes, B.; Vlase, L.; Gagyi, C.E.; Dronca, E.; Miu, A.C.; Dronca, M.
High levels of homocysteine and low serum paraoxonase 1 arylesterase activity in children with autism
Life Sci.
78
2244-2248
2006
Homo sapiens
brenda
Kilic, S.S.; Aydin, S.; Kilic, N.; Erman, F.; Celik, I.
Serum arylesterase and paraoxonase activity in patients with chronic hepatitis
World J. Gastroenterol.
11
7351-7354
2005
Homo sapiens (P27169), Homo sapiens
brenda
Sumegova, K.; Blazicek, P.; Waczulikova, I.; Zitnanova, I.; Durackova, Z.
Activity of paraoxonase 1 (PON1) and its relationship to markers of lipoprotein oxidation in healthy Slovaks
Acta Biochim. Pol.
53
783-787
2006
Homo sapiens (P27169)
brenda
Juretic, D.; Motejlkova, A.; Kunovi?, B.; Reki?, B.; Flegar-Mestri?, Z.; Vuji?, L.; Mesi?, R.; Lukac-Bajalo, J.; Simeon-Rudolf, V.
Paraoxonase/arylesterase in serum of patients with type II diabetes mellitus
Acta Pharm.
56
59-68
2006
Homo sapiens
brenda
Walker, J.P.; Kimble, K.W.; Asher, S.A.
Photonic crystal sensor for organophosphate nerve agents utilizing the organophosphorus hydrolase enzyme
Anal. Bioanal. Chem.
389
2115-2124
2007
Homo sapiens
brenda
Saruhan, E.; Olgun, A.; Oztuerk, K.; Akman, S.; Erbil, M.K.
Age-related paraoxonase activity changes in Turkish population
Ann. N. Y. Acad. Sci.
1100
218-222
2007
Homo sapiens
brenda
Muacevic-Katanec, D.; Bradamante, V.; Poljicanin, T.; Reiner, Z.; Babic, Z.; Simeon-Rudolf, V.; Katanec, D.
Clinical study on the effect of simvastatin on paraoxonase activity
Arzneimittelforschung
57
647-653
2007
Homo sapiens
brenda
Santanam, N.; Parthasarathy, S.
Aspirin is a substrate for paraoxonase-like activity: implications in atherosclerosis
Atherosclerosis
191
272-275
2007
Homo sapiens (P27169), Homo sapiens
brenda
Aslan, M.; Nazligul, Y.; Horoz, M.; Bolukbas, C.; Bolukbas, F.F.; Gur, M.; Celik, H.; Erel, O.
Serum paraoxonase-1 activity in Helicobacter pylori infected subjects
Atherosclerosis
196
270-274
2008
Homo sapiens
brenda
Rochu, D.; Chabriere, E.; Renault, F.; Elias, M.; Clery-Barraud, C.; Masson, P.
Stabilization of the active form(s) of human paraoxonase by human phosphate-binding protein
Biochem. Soc. Trans.
35
1616-1620
2007
Homo sapiens
brenda
Nguyen, S.D.; Sok, D.E.
Preferable stimulation of PON1 arylesterase activity by phosphatidylcholines with unsaturated acyl chains or oxidized acyl chains at sn-2 position
Biochim. Biophys. Acta
1758
499-508
2006
Homo sapiens (P27169)
brenda
Rochu, D.; Renault, F.; Clery-Barraud, C.; Chabriere, E.; Masson, P.
Stability of highly purified human paraoxonase (PON1): Association with human phosphate binding protein (HPBP) is essential for preserving its active conformation(s)
Biochim. Biophys. Acta
1774
874-883
2007
Homo sapiens (P27169)
brenda
Sinan, S.; Kockar, F.; Arslan, O.
Novel purification strategy for human PON1 and inhibition of the activity by cephalosporin and aminoglikozide derived antibiotics
Biochimie
88
565-574
2006
Homo sapiens
brenda
Forrest, S.R.; Elmore, B.B.; Palmer, J.D.
Activity and lifetime of organophosphorous hydrolase (OPH) immobilized using layer-by-layer nano self-assembly on silicon microchannels
Catal. Today
120
30-34
2006
Homo sapiens
-
brenda
Sirivarasai, J.; Kaojarern, S.; Yoovathaworn, K.; Sura, T.
Paraoxonase (PON1) polymorphism and activity as the determinants of sensitivity to organophosphates in human subjects
Chem. Biol. Interact.
168
184-192
2007
Homo sapiens (P27169), Homo sapiens
brenda
Can Demirdoegen, B.; Tuerkanoglu, A.; Bek, S.; Sanisoglu, Y.; Demirkaya, S.; Vural, O.; Arinc, E.; Adali, O.
Paraoxonase/arylesterase ratio, PON1 192Q/R polymorphism and PON1 status are associated with increased risk of ischemic stroke
Clin. Biochem.
41
1-9
2008
Homo sapiens (P27169)
brenda
Schulpis, K.H.; Karikas, G.A.; Bartzeliotou, A.; Papakonstantinou, E.D.; Kalogerakou, M.; Tsakiris, S.
The effect of diet on paraoxonase 1/arylesterase activities in patients with disorders of galactose metabolism
Clin. Endocrinol. (Oxf.)
67
687-692
2007
Homo sapiens (P27169)
brenda
Isik, A.; Koca, S.S.; Ustundag, B.; Celik, H.; Yildirim, A.
Paraoxonase and arylesterase levels in rheumatoid arthritis
Clin. Rheumatol.
26
342-348
2007
Homo sapiens (P27169)
brenda
Catano, H.C.; Cueva, J.L.; Cardenas, A.M.; Izaguirre, V.; Zavaleta, A.I.; Carranza, E.; Hernandez, A.F.
Distribution of paraoxonase-1 gene polymorphisms and enzyme activity in a Peruvian population
Environ. Mol. Mutagen.
47
699-706
2006
Homo sapiens (P27169)
brenda
Schulpis, K.H.; Bartzeliotou, A.; Tsakiris, S.; Gounaris, A.; Papassotiriou, I.
Serum paraoxonase/arylesterase activities in phenylketonuric patients on diet
Eur. J. Clin. Nutr.
61
803-808
2007
Homo sapiens (P27169), Homo sapiens
brenda
Yeung, D.T.; Smith, J.R.; Sweeney, R.E.; Lenz, D.E.; Cerasoli, D.M.
Direct detection of stereospecific soman hydrolysis by wild-type human serum paraoxonase
FEBS J.
274
1183-1191
2007
Homo sapiens
brenda
Renault, F.; Chabriere, E.; Andrieu, J.; Dublet, B.; Masson, P.; Rochu, D.
Tandem purification of two HDL-associated partner proteins in human plasma, paraoxonase (PON1) and phosphate binding protein (HPBP) using hydroxyapatite chromatography
J. Chromatogr. B
836
15-21
2006
Homo sapiens (P27169)
brenda
Gaidukov, L.; Tawfik, D.S.
The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity
J. Lipid Res.
48
1637-1646
2007
Homo sapiens (P27169), Homo sapiens
brenda
Park, C.H.; Nguyen, S.D.; Kim, M.R.; Jeong, T.S.; Sok, D.E.
Differential effect of lysophospholipids on activities of human plasma paraoxonase1, either soluble or lipid-bound
Lipids
41
371-380
2006
Homo sapiens (P27169)
brenda
Kanamori-Kataoka, M.; Seto, Y.
Paraoxonase activity against nerve gases measured by capillary electrophoresis and characterization of human serum paraoxonase (PON1) polymorphism in the coding region (Q192R)
Anal. Biochem.
385
94-100
2009
Homo sapiens (P27169), Homo sapiens
brenda
Abd-Allah, G.M.; Mariee, A.D.
Nitrite-mediated inactivation of human plasma paraoxonase-1: possible beneficial effect of aromatic amino acids
Appl. Biochem. Biotechnol.
150
281-288
2008
Homo sapiens (P27169), Homo sapiens
brenda
Blum, M.M.; Timperley, C.M.; Williams, G.R.; Thiermann, H.; Worek, F.
Inhibitory potency against human acetylcholinesterase and enzymatic hydrolysis of fluorogenic nerve agent mimics by human paraoxonase 1 and squid diisopropyl fluorophosphatase
Biochemistry
47
5216-5224
2008
Homo sapiens (P27169), Homo sapiens
brenda
Kotur-Stevuljevic, J.; Spasic, S.; Jelic-Ivanovic, Z.; Spasojevic-Kalimanovska, V.; Stefanovic, A.; Vujovic, A.; Memon, L.; Kalimanovska-Ostric, D.
PON1 status is influenced by oxidative stress and inflammation in coronary heart disease patients
Clin. Biochem.
41
1067-1073
2008
Homo sapiens (P27169)
brenda
Alici, H.A.; Ekinci, D.; Beydemir, S.
Intravenous anesthetics inhibit human paraoxonase-1 (PON1) activity in vitro and in vivo
Clin. Biochem.
41
1384-1390
2008
Homo sapiens (P27169), Homo sapiens
brenda
Schulpis, K.H.; Barzeliotou, A.; Papadakis, M.; Rodolakis, A.; Antsaklis, A.; Papassotiriou, I.; Vlachos, G.D.
Maternal chronic hepatitis B virus is implicated with low neonatal paraoxonase/arylesterase activities
Clin. Biochem.
41
282-287
2008
Homo sapiens (P27169), Homo sapiens
brenda
Yildiz, A.; Gur, M.; Demirbag, R.; Yilmaz, R.; Akyol, S.; Aslan, M.; Erel, O.
Paraoxonase and arylesterase activities in untreated dipper and non-dipper hypertensive patients
Clin. Biochem.
41
779-784
2008
Homo sapiens (P27169), Homo sapiens
brenda
Barim, A.O.; Aydin, S.; Colak, R.; Dag, E.; Deniz, O.; Sahin, I.
Ghrelin, paraoxonase and arylesterase levels in depressive patients before and after citalopram treatment
Clin. Biochem.
42
1076-1081
2009
Homo sapiens (P27169)
brenda
Kasprzak, M.; Iskra, M.; Majewski, W.; Wielkoszynski, T.
Arylesterase and paraoxonase activity of paraoxonase (PON1) affected by ischemia in the plasma of patients with arterial occlusion of the lower limbs
Clin. Biochem.
42
50-56
2009
Homo sapiens (P27169)
brenda
Garces, C.; Lopez-Simon, L.; Rubio, R.; Benavente, M.; Cano, B.; Ortega, H.; de Oya, M.
High-density lipoprotein cholesterol and paraoxonase 1 (PON1) genetics and serum PON1 activity in prepubertal children in Spain
Clin. Chem. Lab. Med.
46
809-813
2008
Homo sapiens (P27169)
brenda
Kotani, K.; Kimura, S.; Tsuzaki, K.; Sakane, N.; Komada, I.; Schulze, J.; Gugliucci, A.
Reduced paraoxonase 1/arylesterase activity and its post-therapeutic increase in obstructive sleep apnea syndrome: A preliminary study
Clin. Chim. Acta
395
184-185
2008
Homo sapiens (P27169)
brenda
van den Berg, S.W.; Jansen, E.H.; Kruijshoop, M.; Beekhof, P.K.; Blaak, E.; van der Kallen, C.J.; van Greevenbroek, M.M.; Feskens, E.J.
Paraoxonase 1 phenotype distribution and activity differs in subjects with newly diagnosed Type 2 diabetes (the CODAM Study)
Diabet. Med.
25
186-193
2008
Homo sapiens (P27169)
brenda
Liu, Y.; Mackness, B.; Mackness, M.
Comparison of the ability of paraoxonases 1 and 3 to attenuate the in vitro oxidation of low-density lipoprotein and reduce macrophage oxidative stress
Free Radic. Biol. Med.
45
743-748
2008
Homo sapiens (P27169)
brenda
Camuzcuoglu, H.; Arioz, D.T.; Toy, H.; Kurt, S.; Celik, H.; Erel, O.
Serum paraoxonase and arylesterase activities in patients with epithelial ovarian cancer
Gynecol. Oncol.
112
481-485
2009
Homo sapiens (P27169), Homo sapiens
brenda
Rock, W.; Rosenblat, M.; Miller-Lotan, R.; Levy, A.P.; Elias, M.; Aviram, M.
Consumption of wonderful variety pomegranate juice and extract by diabetic patients increases paraoxonase 1 association with high-density lipoprotein and stimulates its catalytic activities
J. Agric. Food Chem.
56
8704-8713
2008
Homo sapiens (P27169)
brenda
Pasca, S.P.; Dronca, E.; Nemes, B.; Kaucsar, T.; Endreffy, E.; Iftene, F.; Benga, I.; Cornean, R.; Dronca, M.
Paraoxonase 1 activities and polymorphisms in autism spectrum disorders
J. Cell. Mol. Med.
14
600-607
2010
Homo sapiens
brenda
Stoltz, D.A.; Ozer, E.A.; Taft, P.J.; Barry, M.; Liu, L.; Kiss, P.J.; Moninger, T.O.; Parsek, M.R.; Zabner, J.
Drosophila are protected from Pseudomonas aeruginosa lethality by transgenic expression of paraoxonase-1
J. Clin. Invest.
118
3123-3131
2008
Homo sapiens (P27169)
brenda
Aksoy, H.; Aksoy, A.N.; Ozkan, A.; Polat, H.
Serum lipid profile, oxidative status, and paraoxonase 1 activity in hyperemesis gravidarum
J. Clin. Lab. Anal.
23
105-109
2009
Homo sapiens (P27169)
brenda
Jaichander, P.; Selvarajan, K.; Garelnabi, M.; Parthasarathy, S.
Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin
J. Lipid Res.
49
2142-2148
2008
Homo sapiens (P27169), Mus musculus (P52430)
brenda
Wills, A.M.; Landers, J.E.; Zhang, H.; Richter, R.J.; Caraganis, A.J.; Cudkowicz, M.E.; Furlong, C.E.; Brown, R.H.
Paraoxonase 1 (PON1) organophosphate hydrolysis is not reduced in ALS
Neurology
70
929-934
2008
Homo sapiens (P27169)
brenda
Stevens, R.C.; Suzuki, S.M.; Cole, T.B.; Park, S.S.; Richter, R.J.; Furlong, C.E.
Engineered recombinant human paraoxonase 1 (rHuPON1) purified from Escherichia coli protects against organophosphate poisoning
Proc. Natl. Acad. Sci. USA
105
12780-12784
2008
Homo sapiens (P27169)
brenda
Hu, X.; Jiang, X.; Lenz, D.E.; Cerasoli, D.M.; Wallqvist, A.
In silico analyses of substrate interactions with human serum paraoxonase 1
Proteins
75
486-498
2009
Homo sapiens (P27169), Homo sapiens
brenda
Richter, R.J.; Jarvik, G.P.; Furlong, C.E.
Paraoxonase 1 (PON1) status and substrate hydrolysis
Toxicol. Appl. Pharmacol.
235
1-9
2009
Homo sapiens (P27169)
brenda
Hsu, Y.T.; Su, C.Y.; Du, H.C.; Jao, S.C.; Li, W.S.
Evaluation of organophosphorus chemicals-degrading enzymes: a comparison of Escherichia coli and human cytosolic aminopeptidase P
Chem. Biodivers.
5
1401-1411
2008
Escherichia coli (P15034), Homo sapiens (Q9NQW7)
brenda
Nguyen, S.D.; Hung, N.D.; Cheon-Ho, P.; Ree, K.M.; Dai-Eun, S.
Oxidative inactivation of lactonase activity of purified human paraoxonase 1 (PON1)
Biochim. Biophys. Acta
1790
155-160
2009
Homo sapiens
brenda
Popa, C.; van Tits, L.J.; Barrera, P.; Lemmers, H.L.; van den Hoogen, F.H.; van Riel, P.L.; Radstake, T.R.; Netea, M.G.; Roest, M.; Stalenhoef, A.F.
Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients
Ann. Rheum. Dis.
68
868-872
2009
Homo sapiens
brenda
Samra, Z.Q.; Shabir, S.; Rehmat, Z.; Zaman, M.; Nazir, A.; Dar, N.; Athar, M.A.
Synthesis of cholesterol-conjugated magnetic nanoparticles for purification of human paraoxonase 1
Appl. Biochem. Biotechnol.
162
671-686
2010
Homo sapiens
brenda
Otto, T.C.; Kasten, S.A.; Kovaleva, E.; Liu, Z.; Buchman, G.; Tolosa, M.; Davis, D.; Smith, J.R.; Balcerzak, R.; Lenz, D.E.; Cerasoli, D.M.
Purification and characterization of functional human paraoxonase-1 expressed in Trichoplusia ni larvae
Chem. Biol. Interact.
187
388-392
2010
Homo sapiens
brenda
Gencer, N.; Arslan, O.
Purification human PON1Q192 and PON1R192 isoenzymes by hydrophobic interaction chromatography and investigation of the inhibition by metals
J. Chromatogr. B
877
134-140
2009
Homo sapiens
brenda
Renault, F.; Carus, T.; Clery-Barraud, C.; Elias, M.; Chabriere, E.; Masson, P.; Rochu, D.
Integrative analytical approach by capillary electrophoresis and kinetics under high pressure optimized for deciphering intrinsic and extrinsic cofactors that modulate activity and stability of human paraoxonase (PON1)
J. Chromatogr. B
878
1346-1355
2010
Homo sapiens, synthetic construct
brenda
Ekinci, D.; Beydemir, S.
Effect of some analgesics on paraoxonase-1 purified from human serum
J. Enzyme Inhib. Med. Chem.
24
1034-1039
2009
Homo sapiens
brenda
Fairchild, S.Z.; Peterson, M.W.; Hamza, A.; Zhan, C.G.; Cerasoli, D.M.; Chang, W.E.
Computational characterization of how the VX nerve agent binds human serum paraoxonase 1
J. Mol. Model.
17
97-109
2011
Homo sapiens
brenda
Camuzcuoglu, H.; Toy, H.; Cakir, H.; Celik, H.; Erel, O.
Decreased paraoxonase and arylesterase activities in the pathogenesis of future atherosclerotic heart disease in women with gestational diabetes mellitus
J. Womens Health (Larchmt)
18
1435-1439
2009
Homo sapiens
brenda
Valiyaveettil, M.; Alamneh, Y.; Biggemann, L.; Soojhawon, I.; Doctor, B.P.; Nambiar, M.P.
Efficient hydrolysis of the chemical warfare nerve agent tabun by recombinant and purified human and rabbit serum paraoxonase 1
Biochem. Biophys. Res. Commun.
403
97-102
2010
Oryctolagus cuniculus, Homo sapiens
brenda
Valiyaveettil, M.; Alamneh, Y.; Rezk, P.; Biggemann, L.; Perkins, M.W.; Sciuto, A.M.; Doctor, B.P.; Nambiar, M.P.
Protective efficacy of catalytic bioscavenger, paraoxonase 1 against sarin and soman exposure in guinea pigs
Biochem. Pharmacol.
81
800-809
2011
Oryctolagus cuniculus, Homo sapiens
brenda
Tsai, P.C.; Bigley, A.; Li, Y.; Ghanem, E.; Cadieux, C.L.; Kasten, S.A.; Reeves, T.E.; Cerasoli, D.M.; Raushel, F.M.
Stereoselective hydrolysis of organophosphate nerve agents by the bacterial phosphotriesterase
Biochemistry
49
7978-7987
2010
Homo sapiens
brenda
Moghtaderi, A.; Hashemi, M.; Dabiri, S.; Moazeni-Roodi, A.; Hosseini, M.
Serum paraoxonase and arylesterase activities in patients with lacunar infarction: a case control study
Clin. Biochem.
44
288-292
2011
Homo sapiens
brenda
Hashemi, M.; Kordi-Tamandani, D.M.; Sharifi, N.; Moazeni-Roodi, A.; Kaykhaei, M.A.; Narouie, B.; Torkmanzehi, A.
Serum paraoxonase and arylesterase activities in metabolic syndrome in Zahedan, southeast Iran
Eur. J. Endocrinol.
164
219-222
2011
Homo sapiens
brenda
Cayir, K.; Bilici, M.; Tekin, S.; Kara, F.; Turkyilmaz, A.; Yildirim, A.
Serum paraoxonase and arylesterase activities in esophageal cancer: A controlled study
Eur. J. Gen. Med.
7
398-403
2010
Homo sapiens
-
brenda
Bayrak, A.; Bayrak, T.; Demirpence, E.; Kilinc, K.
Differential hydrolysis of homocysteine thiolactone by purified human serum (192)Q and (192)R PON1 isoenzymes
J. Chromatogr. B
879
49-55
2011
Homo sapiens
brenda
Duygu, F.; Tekin Koruk, S.; Aksoy, N.
Serum paraoxonase and arylesterase activities in various forms of hepatitis B virus infection
J. Clin. Lab. Anal.
25
311-316
2011
Homo sapiens
brenda
Kockar, F.; Sinan, S.; Yildirim, H.; Arslan, O.
Differential effects of some antibiotics on paraoxonase enzyme activity on human hepatoma cells (HepG2) in vitro
J. Enzyme Inhib. Med. Chem.
25
715-719
2010
Homo sapiens
brenda
Valiyaveettil, M.; Alamneh, Y.; Biggemann, L.; Soojhawon, I.; Farag, H.A.; Agrawal, P.; Doctor, B.P.; Nambiar, M.P.
In vitro efficacy of paraoxonase 1 from multiple sources against various organophosphates
Toxicol. In Vitro
25
905-913
2011
Oryctolagus cuniculus, Homo sapiens
brenda
Trovaslet-Leroy, M.; Musilova, L.; Renault, F.; Brazzolotto, X.; Misik, J.; Novotny, L.; Froment, M.T.; Gillon, E.; Loiodice, M.; Verdier, L.; Masson, P.; Rochu, D.; Jun, D.; Nachon, F.
Organophosphate hydrolases as catalytic bioscavengers of organophosphorus nerve agents
Toxicol. Lett.
206
14-23
2011
Brevundimonas diminuta, Homo sapiens
brenda
Erzengin, M.; Basaran, I.; Cakir, U.; Aybey, A.; Sinan, S.
In vitro inhibition effect of some dihydroxy coumarin compounds on purified human serum paraoxonase 1 (PON1)
Appl. Biochem. Biotechnol.
168
1540-1548
2012
Homo sapiens
brenda
Bajaj, P.; Aggarwal, G.; Tripathy, R.K.; Pande, A.H.
Interplay between amino acid residues at positions 192 and 115 in modulating hydrolytic activities of human paraoxonase 1
Biochimie
105
202-210
2014
Homo sapiens (P27169), Homo sapiens
brenda
Kirbas, A.; Kirbas, S.; Anlar, O.; Efe, H.; Yilmaz, A.
Serum paraoxonase and arylesterase activity and oxidative status in patients with multiple sclerosis
J. Clin. Neurosci.
20
1106-1109
2013
Homo sapiens
brenda
Kirbas, A.; Kirbas, S.; Cure, M.C.; Tufekci, A.
Paraoxonase and arylesterase activity and total oxidative/anti-oxidative status in patients with idiopathic Parkinson's disease
J. Clin. Neurosci.
21
451-455
2014
Homo sapiens
brenda
Kati, C.; Karadas, S.; Aslan, M.; Gonullu, H.; Duran, L.; Demir, H.
Serum paraoxonase and arylesterase activities and oxidative stress levels in patients with SSRI intoxication
J. Membr. Biol.
247
17-21
2014
Homo sapiens
brenda
Bajaj, P.; Tripathy, R.K.; Aggarwal, G.; Pande, A.H.
Characterization of human paraoxonase 1 variants suggest that His residues at 115 and 134 positions are not always needed for the lactonase/arylesterase activities of the enzyme
Protein Sci.
22
1799-1807
2013
Homo sapiens (P27169), Homo sapiens
brenda
Olama, S.M.; Elarman, M.M.
Evaluation of paraoxonase and arylesterase activities in Egyptian patients with ankylosing spondylitis
Rheumatol. Int.
33
1487-1494
2013
Homo sapiens
brenda
Tekin Koruk, S.; Aksoy, N.; Hamidanoglu, M.; Karsen, H.; Unlu, S.; Bilinc, H.
The activity of paraoxonase and arylesterase in patients with osteomyelitis
Scand. J. Clin. Lab. Invest.
72
513-517
2012
Homo sapiens
brenda
Chambers, J.E.; Chambers, H.W.; Meek, E.C.; Funck, K.E.; Bhavaraju, M.H.; Gwaltney, S.R.; Pringle, R.B.
Novel nucleophiles enhance the human serum paraoxonase 1 (PON1)-mediated detoxication of organophosphates
Toxicol. Sci.
143
46-53
2015
Homo sapiens
brenda
Abulimite, Z.; Mu, X.; Xiao, S.; Liu, M.; Li, Q.; Chen, G.
New chemiluminescent substrates of paraoxonase 1 with improved specificity synthesis and properties
Appl. Biochem. Biotechnol.
176
301-316
2015
Homo sapiens (P27169)
brenda
Tripathy, R.K.; Aggarwal, G.; Bajaj, P.; Kathuria, D.; Bharatam, P.V.; Pande, A.H.
Towards understanding the catalytic mechanism of human paraoxonase 1 experimental and in silico mutagenesis studies
Appl. Biochem. Biotechnol.
182
1642-1662
2017
Homo sapiens, Homo sapiens (P27169)
brenda
Lyagin, I.V.; Andrianova, M.S.; Efremenko, E.N.
Extensive hydrolysis of phosphonates as unexpected behaviour of the known His6-organophosphorus hydrolase
Appl. Microbiol. Biotechnol.
100
5829-5838
2016
Homo sapiens (P27169)
brenda
Kul, A.; Uzkeser, H.; Ozturk, N.
Paraoxonase and arylesterase levels in Behcets disease and their relations with the disease activity
Biochem. Genet.
55
335-344
2017
Homo sapiens
brenda
Ashani, Y.; Leader, H.; Aggarwal, N.; Silman, I.; Worek, F.; Sussman, J.L.; Goldsmith, M.
Invitro evaluation of the catalytic activity of paraoxonases and phosphotriesterases predicts the enzyme circulatory levels required for invivo protection against organophosphate intoxications
Chem. Biol. Interact.
259
252-256
2016
Pseudomonas sp., Brevundimonas diminuta (P0A434), Homo sapiens (P27169), Agrobacterium tumefaciens (Q93LD7)
brenda
Ponce-Ruiz, N.; Murillo-Gonzalez, F.E.; Rojas-Garcia, A.E.; Mackness, M.; Bernal-Hernandez, Y.Y.; Barron-Vivanco, B.S.; Gonzalez-Arias, C.A.; Medina-Diaz, I.M.
Transcriptional regulation of human paraoxonase 1 by nuclear receptors
Chem. Biol. Interact.
268
77-84
2017
Homo sapiens (P27169)
brenda
Zsiros, N.; Koncsos, P.; Lorincz, H.; Seres, I.; Katko, M.; Szentpeteri, A.; Varga, V.E.; Fueloep, P.; Paragh, G.; Harangi, M.
Paraoxonase-1 arylesterase activity is an independent predictor of myeloperoxidase levels in overweight patients with or without cardiovascular complications
Clin. Biochem.
49
862-867
2016
Homo sapiens
brenda
Arulkumar, M.; Vijayan, R.; Penislusshiyan, S.; Sathishkumar, P.; Angayarkanni, J.; Palvannan, T.
Alteration of paraoxonase, arylesterase and lactonase activities in people around fluoride endemic area of Tamil Nadu, India
Clin. Chim. Acta
471
206-215
2017
Homo sapiens
brenda
Millenson, M.E.; Braun, J.M.; Calafat, A.M.; Barr, D.B.; Huang, Y.T.; Chen, A.; Lanphear, B.P.; Yolton, K.
Urinary organophosphate insecticide metabolite concentrations during pregnancy and childrens interpersonal, communication, repetitive, and stereotypic behaviors at 8 years of age the home study
Environ. Res.
157
9-16
2017
Homo sapiens (P27169)
brenda
Bizon, A.; Milnerowicz, H.
The effect of divalent metal chelators and cadmium on serum phosphotriesterase, lactonase and arylesterase activities of paraoxonase 1
Environ. Toxicol. Pharmacol.
58
77-83
2018
Homo sapiens
brenda
Kahveci, H.; Laloglu, F.; Kilic, O.; Ciftel, M.; Yildirim, A.; Orbak, Z.; Ertekin, V.; Laloglu, E.
Serum paraoxonase and arylesterase values as antioxidants in healthy premature infants at fasting and posprandial times
Eur. Rev. Med. Pharmacol. Sci.
19
1761-1765
2015
Homo sapiens
brenda
Cebi, A.; Akgun, E.; Esen, R.; Demir, H.; Cifci, A.
The activities of serum paraoxonase and arylesterase and lipid profile in acute myeloid leukemia preliminary results
Eur. Rev. Med. Pharmacol. Sci.
19
4590-4594
2015
Homo sapiens
brenda
Zargari, M.; Sharafeddin, F.; Mahrooz, A.; Alizadeh, A.; Masoumi, P.
The common variant Q192R at the paraoxonase 1 (PON1) gene and its activity are responsible for a portion of the altered antioxidant status in type 2 diabetes
Exp. Biol. Med.
241
1489-1496
2016
Homo sapiens
brenda
Perla-Kajan, J.; Borowczyk, K.; Glowacki, R.; Nygard, O.; Jakubowski, H.
Paraoxonase 1 Q192R genotype and activity affect homocysteine thiolactone levels in humans
FASEB J.
32
6019
2018
Homo sapiens
brenda
Aggarwal, G.; Prajapati, R.; Tripathy, R.K.; Bajaj, P.; Iyengar, A.R.; Sangamwar, A.T.; Pande, A.H.
Toward understanding the catalytic mechanism of human paraoxonase 1 site-specific mutagenesis at position 192
PLoS ONE
11
e0147999
2016
Homo sapiens (P27169), Homo sapiens
brenda
Bajaj, P.; Tripathy, R.K.; Aggarwal, G.; Pande, A.H.
Expression and purification of biologically active recombinant human paraoxonase 1 from inclusion bodies of Escherichia coli
Protein Expr. Purif.
115
95-101
2015
Homo sapiens (P27169), Homo sapiens
brenda
Yun, H.; Yu, J.; Kim, S.; Lee, N.; Lee, J.; Lee, S.; Kim, N.D.; Yu, C.; Rho, J.
Expression and purification of biologically active recombinant human paraoxonase 1 from a Drosophila S2 stable cell line
Protein Expr. Purif.
131
34-41
2017
Homo sapiens (P27169)
brenda
Korkmaz, H.; Tabur, S.; Ozkaya, M.; Oguz, E.; Elboga, U.; Aksoy, N.; Akarsu, E.
Paraoxonase and arylesterase levels in autoimmune thyroid diseases
Redox Rep.
21
227-231
2016
Homo sapiens
brenda
Korkmaz, H.; Tabur, S.; Oezkaya, M.; Aksoy, N.; Yildiz, H.; Akarsu, E.
Paraoxonase and arylesterase activities in patients with papillary thyroid cancer
Scand. J. Clin. Lab. Invest.
75
259-264
2015
Homo sapiens
brenda